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 Brucellosis, a zoonotic disease caused by Brucella spp., presents both health and 
economic difficulties for livestock, wildlife, and humans.  While brucellosis is nearly 
eradicated in the United States, the disease remains detrimental in many countries 
worldwide.   
 Attempts to produce a safe and effective small ruminant vaccine have been met 
with limited success.  The current vaccine for bovine brucellosis in the United States is B. 
abortus RB51.  This strain transiently colonizes the host and induces a cell-mediated 
immune response.  Levels of protection have not been demonstrated in goats and thus it is 
considered a relatively poor caprine vaccine that probably does not survive long enough 
in the tissues to produce a sufficient protective immune response.   
 This study analyzes the possibility of using RB51 containing plasmid QAE for 
vaccination in goats.  The plasmid QAE contains a gene region of DNA from B. 
melitensis 16M hypothesized to encode for a putative hemagglutinin that is believed to be 
a host specificity protein.  The region E gene sequence is not present in any strain of B. 
abortus, including RB51.  It is proposed that the addition of region E to RB51 will 
enhance survivability in the caprine host to the extent where an adequate protective 
immune response is elicited.   
 The QAE plasmid was electroporated into B. abortus RB51 and screened using 
ampicillin resistance as a selective measure.  Ten goats were conjunctivally inoculated 
with RB51-QAE, the modified strain, and ten goats received strain RB51 in the same 
manner as controls.  Two goats from each group were euthanized and necropsied at 
weekly intervals for four weeks and again at 42 days.  Tissues from these animals were 
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taken at necropsy and used to collect data for colonization and histopathology.  Serum 
samples were also analyzed for Brucella-specific antibodies.  Both strains transiently 
colonized the hosts without producing any detrimental pathology.  However, the RB51-
QAE goats demonstrated higher levels of colonization and greater humoral immune 
responses for longer periods of time.  These are very promising findings as the levels of 
colonization and humoral responses may correspond with better protection.  These results 
warrant further testing of RB51-QAE as a potential vaccine for caprine brucellosis. 
 The putative hemagglutinin was characterized using hemagglutination assays, 
absorption assays, and mass spectrometry analysis following 2D gel electrophoresis.  The 
region E protein was found to provide RB51-QAE with increased hemagglutinating and 
immunogenic capabilities.  Furthermore, there is evidence to suggest that the protein is a 
cell surface protein, not excreted from the cell. 
 The accepted gold standard for the detection of brucellae is bacterial culture.  
PCR is being evaluated as a possible alternative detection method for Brucella spp. in 
bodily fluids such as blood and urine.  Currently, there is no accepted standard for 
detection of brucellae using PCR.    
 The effects of template preparation, primer selection, and PCR optimization on 
the limit of detection for B. abortus 2308 and B. melitensis 16M in association with 
whole blood, plasma, or urine were examined.  Ten-fold dilutions were made from a 
known number of bacterial cells in each of the fluids tested.  The practices of using whole 
killed cells as a direct template for PCR as well as two differing DNA isolation 
techniques were evaluated for each fluid dilution.  Our findings suggest that a more 
extensive template preparation technique and PCR protocol elongation can greatly 
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improve the limit of detection capabilities.  Biological fluids provided dissimilar results 
based on the PCR inhibition properties of the fluid and DNA isolation techniques.  The 
results of this experiment encourage further investigation into the optimization of 
conventional PCR techniques as a faster and more efficient diagnostic tool for Brucella 
spp. in humans and animals. 
 
INTRODUCTION 
 Brucellae are aerobic, Gram-negative, facultative intracellular pathogens that are 
the causative agents of brucellosis in both humans and animals.  Brucella abortus is 
responsible for bovine brucellosis and in other primary hosts such as moose, elk, and 
bison.  Secondary hosts of B. abortus include goats, sheep, pigs, and humans.  Brucella 
melitensis is the most virulent Brucella spp. and infects mainly goats, although humans 
are a secondary host.  Other species of Brucella include B. suis, B. ovis, and B. canis.  
These species infect pigs, sheep, and dogs, respectively, as primary hosts.  A recently 
proposed species, B. microti, infects voles and foxes and is genetically homologous to 
other species of brucellae.  There are also two species, B. ceti and B. pinnipedialis, found 
to infect marine mammals as primary hosts and current research suggests that both are 
zoonotic pathogens (Foster et al. 2007).  Three species, B. melitensis, B. abortus, and B. 
suis, are considered agents of bioterrorism by the United States Centers for Disease 
Control and Prevention because they are easily disseminated, highly contagious, and 
stable under conditions of production and storage.  Widespread disease would pose a 
threat to public health for humans and companion animals, and have devastating effects 
on the agricultural industry. 
 Transmission among animals is most often through direct contact of contaminated 
substances with the mucous membranes.  Human infection occurs through direct contact 
with infected animals and the consumption of their unpasterurized dairy products.  The 
disease is not transmitted from human to human.  Other modes of transmission can occur 
through contact with abraded skin and aerosolization.  Once in a susceptible host, 
brucellae eventually disseminate throughout the host, colonizing tissues and affecting 
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several systems detrimentally.  Human brucellosis is primarily characterized by 
undulating fever.  Animal brucellosis is characterized by abortions and other pathologies 
of the reproductive organs, as well as joint abnormalities.   
 Standard diagnosis of Brucella infection is performed by blood testing and 
culture.  Serologic diagnosis is not foolproof and can provide false positive results due to 
antibodies produced by smooth vaccine strains or other bacteria with homologous 
antigenic determinants.  Bacterial culture is a long process and brucellosis may not be 
correctly diagnosed for several days to weeks following sample collection.  Furthermore, 
a faster, more efficient, and reliable diagnostic method would improve the detection and 
treatment capabilities of brucellosis in both humans and animals.   
 Complete genomic sequences have been published for several species of Brucella, 
which have been essential in the discovery and characterization of virulence factors 
employed by the organism under both in vitro and in vivo conditions.  This study focuses 
on the characterization of a putative hemagglutinin gene, named region E, located on the 
chromosome of B. melitensis 16M that is absent in all strains of B. abortus (Perry 2007).  
Protein characterization was performed under both in vitro conditions and in vivo in the 
caprine model comparing a vaccine strain of B. abortus RB51 to a strain containing the 
putative hemagglutinin gene expressed in trans, B. abortus RB51-QAE.  These 
experiments were carried out for the purpose of characterizing the region E putative 
hemagglutinin and evaluating its potential role in the development of a more effective 
rough vaccine.  Rough vaccines are not highly effectual in small ruminants and the 
development of a more efficacious vaccine would contribute tremendously to the 
eradication efforts in endemic countries. 
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 PCR has been explored as an improved technique for the diagnosis of brucellosis 
in humans and animals.  There is currently no standardized technique for brucellae and 
findings have been mixed.  This study explored the limit of detection of Brucella cells by 
conventional PCR in several easily-attainable bodily fluids to explore the possibility of 










































 Bacteria in the genus Brucella are the causative agents of brucellosis in humans 
and animals.  Brucella spp. are important zoonotic and agricultural pathogens that infect 
a wide range of hosts with varying degrees of pathology.  Although rare in the United 
States, brucellosis in both humans and animals remains a threat to public health and 
agricultural economy in endemic areas. 
 Human brucellosis is uncommon in the United States with an estimated 100 cases 
annually.  The disease poses more serious problems in underdeveloped countries around 
the world (Sauret et al. 2002, Seleem et al. 2009).  Affected regions worldwide include 
Latin America, southern Europe, the Middle East, areas in Asia and Africa, and countries 
of the former Soviet Union.  Classical species of Brucella that are infectious to humans 
include B. melitensis (biovars 1-3), B. abortus (biovars 1-6, 9), and B.suis (biovars 1,3,4).  
B. canis infections occur in immunocompromised individuals, but only rarely.  There is 
no approved vaccine for protection in humans and vaccines approved for use in animals 
are infectious to humans.  Transmission is most commonly through ingestion of 
unpasteruized milk from an infected animal, direct contact with infected birth materials, 
or during slaughter.  Infection of humans is also possible through the aerosol route 
(Heymann 2004, Smither et al. 2009).  Although a reportable disease in most countries, it 
is believed that the actual number of reported cases worldwide represents only a portion 
of the actual cases (Sauret et al. 2002, Seleem et al. 2009). 
 Brucellosis is nearly eradicated in domestic animals in the United States through a 
system of successful vaccination regimes and diagnostic testing procedures.   Currently, 
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domestic livestock in the United States are routinely tested for brucellosis using 
standardized diagnostic procedures, such as the Rose Bengal and the Plate Agglutination 
test, which are used to screen domestic herds (Robinson 2003).  Those animals found to 
be brucellosis suspects are subjected to further testing, and if confirmed positive, are 
slaughtered for removal from the herd population (USDA 2006).  Additional serological 
tests are then conducted periodically following the removal of brucellosis seropositive 
animals until the herd is considered completely negative (Ragan 2002). Prevention by 
vaccination is a key tool in the eradication of brucellosis through preventative measures 
and is implemented in domestic herds in the United States (USDA 2006).  The current 
vaccine used in the United States is the B. abortus RB51 rough vaccine, which replaced 
the B. abortus Strain 19 (S19) smooth vaccine in 1996 following complications in 
diagnostic testing with S19 (USDA 1996).   
 Continued herd management is crucial in the eradication program.  Herd 
management procedures assess the risk of a herd becoming exposed to and acquiring 
brucellosis, implementing measures to reduce that risk, and perform routine testing to 
ensure early detection (USDA 2008).  Domestic livestock, especially those herds located 
in areas that are high-risk for exposure, are routinely tested and closely monitored for any 
signs of brucellosis and the occurrence of any abortions are thoroughly investigated.  
Herds found to include brucellosis positive animals are quarantined until further testing 
clears the herd of any suspect infections.  Furthermore, any additions to a herd are tested 
and confirmed brucellosis negative before entering the population (USDA 2006).  The 
control measures of this eradication program have proven successful in eliminating the 
disease from domestic livestock in the United States (USDA 2008).   
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 Because it is more difficult to test wild animals, the status of brucellosis in 
wildlife is not fully understood.  Specifically, free-ranging elk and bison in the Greater 
Yellowstone Area (GYA) pose the greatest obstacle to complete eradication in the United 
States.  Feed grounds have been developed where grazing herds of possibly infected wild 
and domestic animals frequently congregate and intermingle.  Because brucellosis is 
spread primarily through contact with the fluid secretions, such as mucus, milk, maternal 
and fetal tissues and other byproducts of abortion, one infected animal can quickly infect 
several grazing herds through contact or exposure at a single feeding ground.  Studies 
have shown that fluids from infected animals that are deposited on the ground can remain 
infective to other animals for periods of over 100 days, given the sample is in a cold, 
shaded environment (Timoney et al. 1988).   
 B. melitensis, B. abortus, and B. suis are designated as class B, biosafety level 3 
select agents by the Centers for Disease Control and Prevention.  These species are 
infectious to humans and are easily disseminated for potential weaponization (Pappas et 
al. 2006).  Brucellosis as a bioterrorist agent has the potential to cause devastating 
consequences for agricultural and public health systems. 
 Brucella spp. are Gram-negative, non-motile, non-encapsulated coccobacilli that 
are the causative agents of brucellosis in animals and humans (Corbel 1997).  Most, but 
not all, species express a complete lipopolysaccharide (LPS) outer membrane component.   
The LPS provides protection from certain host defenses and structural support.  The 
outermost fraction of the LPS is the O-polysaccharide group (OPS) which 
compositionally unique in Brucella spp. and highly antigenic.  Species of Brucella that 
express a functional OPS group are designated as “smooth”, whereas species that do not 
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express a functional OPS group are designated “rough”.  Ideal laboratory growth of 
brucellae is performed with selective, nutrient-enriched media in an aerobic 5% CO2 
atmosphere at 37°C over a period of 48-72 hours.  Most classical species of brucellae 
provide a positive reaction for catalase, oxidase, and urease tests, with the exception of B. 
ovis, which is oxidase and urease negative, and B. neotomae, which is oxidase negative 
(Yagupsky et al. 2005).    
Pathology 
  
 Once an animal or individual becomes infected with the Brucella pathogen, the 
bacterium travel in the lymph to the nearest draining lymph node and then into the blood 
stream of the host animal.  Brucella spp. avoid destruction by the host’s innate immune 
system with an ability to avoid lysosomal degradation after being engulfed by host 
macrophages (Celli 2006).  Furthermore, Brucella spp. thrive and proliferate inside of the 
host macrophage, and ultimately cause the death of that macrophage, releasing the 
multiplied bacteria back into host tissues.  Once the host becomes bacteremic, the 
pathogen migrates throughout the body to different organs and tissues (Cheers et al. 
1984).   
 The most common pathology of brucellosis in animals is the abortion of the first 
pregnancy that occurs after the onset of the disease.   Most Brucella spp. proliferate 
efficiently in the cells of the body with high erythritol levels, such as the cells found in 
the urinary and reproductive tracts (Enright 1990).  Once in the uterus, the bacteria can 
penetrate the epithelial cells of the embryonic membrane and cause placentitis, which can 
lead to a decrease in the blood supply to the fetus.  Fetuses recovered from brucella 
infected mothers have also been shown to develop edema and congestion in their lungs 
 7
and hemorrhages in their epicardium.  Whether the cause is a decrease in oxygenated 
blood due to an inflamed placenta or the detrimental lesions formed by the infection of 
the fetus, the final outcome of pregnancy is either an abortion or a weak fetus that dies 
shortly after birth (Enright 1990). 
 Other effects on the reproductive system of animals with brucellosis include the 
swelling of the testes and epididymus of male animals.  As in the uterus, Brucella in the 
male urogenital tract can also cause inflammation and swelling of the male reproductive 
organs.  Orchitis and epididymitis are common symptoms of brucellosis in animals, 
causing sterility in infected males.  Most, if not all,  Brucella species can be isolated from 
semen, and males can shed the bacterium for prolonged periods (Iowa 2009).  Brucellosis 
is also responsible for arthritis of the joints and spondylitis in many infected animals as 
well as hygroma formation on the knees.  Brucellosis can also be responsible for mastitis 
in females, neurologic swelling and splenic abscesses with edema, congestion, and 
hemorrhage in the lung and heart. 
 Granulomatous inflammation is also observed during persistent Brucella 
infections.  The exudate of granulomatous inflammation is generally composed of mature 
macrophages, which gravitate to the area of the body affected by the causative agent 
(McLaughlin 2007).  Here, macrophages have the potential to form into multinucleate 
giant cells.  Multinucleate giant cells are a hallmark of infections involving pathogens 
that thrive within phagocytes, as infected macrophages are identified and engulfed by 
other macrophages in a process that results in the formation of a giant cell composed of 
several responding phagocytes (McLaughlin 2007, Abbas 2005).  Fibrosis and necrosis 
are often associated with granulomatous inflammation, especially in the case of 
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granuloma formation.  Granuloma formation is primarily a product of chronic delayed-
type hypersensitivity and occurs in cases of chronic brucellosis.  In a persistent infection 
and subsequent immune response, the lytic and anti-pathogenic actions of non-specific 
phagocytes begin to damage host tissue.  In a chronic infection, this is sometimes 
manifested as the formation of fibrosis and scar tissue surrounding the site of 
inflammation, which has the potential to cause tissue damage that may disrupt normal 
tissue function (Merck 2007).  Necrosis formation in the center of granulomas may occur 
due to anoxic conditions and may function to eliminate infected macrophages, destroying 
the pathogen within (Abbas 2005). 
Species of Brucella 
 Brucella melitensis 
 
 Originally named “Micrococcus melitensis”, Brucella melitensis was discovered 
by Lieutenant Colonel David Bruce in 1887 from British soldiers residing in Malta.  
Brucella  melitensis is a world-wide disease which remains most problematic in 
developing countries.  Although considered to be eradicated in the United States, B. 
melitensis is a continuing cause for concern because of its status as a potential agent of 
biological warfare (Moreno et al. 2002). 
 The primary host of B. melitensis is the caprine host as well as the ovine host, 
although the pathogen can be problematic in cattle, camels, and humans as secondary 
hosts (Nielson et al. 1990).  In female goats and sheep the primary symptom is abortion, 
but larger doses of the pathogen cause mastitis and joint problems.  In male goats, 
orchitis is uncommon, and if observed it is generally unilateral.  In male sheep, however, 
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the disease is often asymptomatic, although orchitis and hygromas are a rare observation 
(Alton 1990). 
 The only approved vaccine against B. melitensis is the Rev.1 vaccine, developed 
from a laboratory strain of B. melitensis 16M.  This vaccine, although effective, is 
potentially abortigenic and produces anti-LPS antibodies that can interfere with 
diagnostic tests (Gonzalez et al. 2008, Blasco 2006).  Vaccines developed from strains of 
B. abortus are not effective in providing protection against infection with B. melitensis.   
 B. melitensis is the most virulent strain in human infection, with only 1-10 
organisms needed for infection and with undulant fever as the primary symptom (Mantur 
et al. 2007).  There is no human vaccine for brucellosis and the B. melitensis Rev.1 
vaccine for animals is infectious to humans (Seleem et al. 2009).  Brucella melitensis is 
highly contagious and can be easily disseminated with devastating effects to public and 
agricultural health. B. melitensis, as well as B. suis and B. abortus, have been deemed 
potential bioterrorism agents by the United States Centers for Disease Control and 
Prevention.   
 Brucella abortus 
 
 Brucella abortus is the agent responsible for the majority of bovine brucellosis 
cases.  It was discovered in 1897 by Bernhard Bang and the disease was originally called 
“Bang’s disease” (Mochman et al. 1988).  In 1918 Alice Evans linked B. abortus with the 
previously discovered B. melitensis and showed that both were agents of brucellosis in 
humans and animals (Parascandola 1998).  Brucella abortus is distributed worldwide and 
is still somewhat problematic in the United States, with wildlife remaining the most 
prevalent reservoir. 
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 Primary hosts include cattle, bison and elk, but goats, sheep, pigs, and humans are 
also susceptible as secondary hosts. Affected cattle typically experience a permanent 
infection, shedding the bacterium for the duration of their lives (Nielson et al. 1990).  The 
disease is spread easily through direct contact and an entire herd can quickly become 
compromised with the inclusion of a single infected animal.    Bovine brucellosis is a 
disease that primarily targets the reproductive system of cattle (Enright 1990).  Infected 
cows typically experience joint ailments, a decrease in milk production, sterility, and 
abortion of the first pregnancy that occurs after the onset of infection (Nielson et al. 
1990).  In bulls, orchitis can develop.  Although rare in the United States in domestic 
cattle today, B. abortus remains a threat to wildlife species such as moose, elk, caribou, 
and bison.   
 Brucella abortus in wildlife, particularly in the Greater Yellowstone area (GYA), 
is difficult to control and monitor.  The presence of brucellosis in the GYA was first 
described in 1917 and it has persisted in Yellowstone bison and elk herds ever since.  
Domestic cattle in and around the GYA may contract brucellosis from these reservoirs 
(Davis and Elzer 2002).  For this reason, the prevalence of brucellosis in free-ranging 
wildlife of the GYA has proven to be a major hindrance in efforts to eradicate the disease 
completely in the United States.  Management practices implemented for the eradication 
of brucellosis in domestic herds are not as easily applied to wildlife.  Diagnostic testing 
and removal of infected animals are difficult due to the relative inaccessibility of animals 
and migration through multiple management jurisdictions (Etter and Drew 2006).  
Vaccines developed for use in domestic livestock have shown a lesser effectiveness in 
wildlife and present difficulties in terms of vaccine delivery (Davis and Elzer 2002).   
 11
 Vaccination against B. abortus has proven an important tool in eradication of the 
disease.  The first brucellosis vaccine approved for commercial use was labeled Strain 19 
(S19) and was derived from a field strain of B. abortus (Sanmartino 2005).  However, 
S19 is a smooth organism and induces the production of antibodies that interfere with 
diagnostic tests.  For this reason, a rough B. abortus vaccine, termed RB51, was 
developed from a laboratory strain of B. abortus 2308 and was shown to be equally 
efficacious as S19 and did not hinder serological testing (Schurig 2002, 1991).  RB51 
remains the only approved vaccine against B. abortus in the United States. 
 Humans, although not a primary host, can contract brucellosis through contact 
with infected animals. Brucella abortus is moderately infectious to humans, with an 
estimated 1 × 105 organisms needed for infection and the primary symptom is undulant 
fever.  While B. melitensis is a more frequent and wide-spread zoonosis, B. abortus 
infects mainly occupational groups working closely with the organism or infected 
animals (Seleem et al. 2009).  Brucella abortus vaccines approved for use in animals, 
such as S19 and RB51, are infectious to humans and there remains no vaccine available 
for human use against B. abortus.  The largest economic and sociological threat from B. 
abortus is to that of the cattle industry, where it is capable of severe economic damage.   
 Brucella suis 
 Swine brucellosis was first reported in 1914 in a government report by Traum 
(Traum 1914) and was assumed to be caused by a strain of B. abortus.  It was not until 
1929 that the disease pathogen was recognized as closely-related, yet separate from B. 
abortus and renamed B. suis, denoting the primary host (Huddleson, 1929).  Brucella suis 
maintains a serious presence in feral swine and has not been eradicated from domestic 
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swine in the United States.  All states, with the exception of Texas, maintained a swine-
brucellosis-free status as of 2008 (USDA 2008), but Florida and Hawaii remain 
problematic areas.   The intermingling of domestic swine with a largely infected feral 
swine population poses an obstacle in eradication of the disease from commercial swine 
herds.   
 Brucella suis is most often described in pigs, but reindeer are also a primary host 
for B. suis biovar 4.  Secondary hosts include cattle, horses, dogs, and humans.  
Transmission is most often accomplished through direct contact with the reproductive 
byproducts of infected sows.  An additional aspect of B. suis transmission is that the 
organism can also be transmitted venereally from infected boars (Alton 1990).  The 
disease in swine is similar pathogenically to brucellosis in other animals.  The most 
common symptom is the incidence of abortions in pregnant females, but other symptoms 
unrelated to the reproductive organs may occur, such as pain in the joints and spondylitis 
(Conger et al. 1999).  Brucella suis often presents a prolonged bacteremic phase in swine 
which can last up to 34 weeks (Alton 1990).  Brucella infected herds of reindeer have 
been recorded across the northernmost regions of North America, with the majority of 
infections occurring in the Arctic Circle (Zarnke 2001, Tessaro et al. 1986).  There are 
currently no vaccines derived from any B. suis strain and no commercially available 
vaccine against B. suis infection for humans or animals in the United States.  Studies 
focused on the development of an effective B. suis vaccine are ongoing. 
 B. suis is moderately to highly infectious to humans, requiring contact with 
approximately 1×103-1×104 organisms for infection.  Because of the lengthy bacteremic 
phase seen in swine, people working with infected pigs are at a higher risk of contracting 
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brucellosis than those working with other animals (Conger et al. 1999).  The highest risk 
for contracting brucellosis through B. suis is seen in people working in close proximity 
with the pathogen or infected animals.  Undulant fever remains the primary symptom in 
individuals infected with B. suis.  This pathogen was weaponized via the M33 cluster 
bomb by the United States in 1955 and all known US stocks were destroyed by the mid-
1990s (Smart 2008, Croddy et al. 2005).  
 Brucella ovis 
 
 Brucella ovis was originally described in New Zealand and Australia by 
McFarland et al. and Simmons et al., respectively (Blasco 1990).  Brucella ovis is most 
prevalent in areas associated with sheep farming and cases have been recorded in New 
Zealand, Australia, North and South America, South Africa, and several European 
countries (Iowa 2009).  Brucella ovis differs from the previously discussed species in that 
it is a naturally rough strain that is infectious even without an intact lipopolysaccharide 
(LPS), which lacks the O-polysaccharide side chain (OPS) (Buddle 1956).  Other 
differences are noted in biochemical tests in that B. ovis is found to be oxidase and urease 
negative, whereas B. melitensis, B. abortus, and B. suis are positive for both. 
 Brucella ovis primarily infects rams while ewes and goats serve as other hosts for 
the organism.  This pathogen has also been documented to infect farmed red deer in New 
Zealand.  Transmission is often venereal and ewes carry the pathogen vaginally for two 
months or more and shed the bacterium in their vaginal discharges and milk.  Infected 
rams have been shown to shed the bacterium in semen for up to 4 years or longer and 
shedding in the urine has also been documented (Iowa 2009, Cerri et al. 1999).  As with 
other previously discussed species, direct contact with infected mucus membranes is 
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another route of transmission.  The incubation period in rams is as long as 3-8 weeks 
post-inoculation.  Symptoms of B. ovis in rams include orchitis, epididymitis, and 
impaired fertility or sterility.  Ewes are less likely to show symptoms if infected, but 
infrequent abortions and placentitis can occur (Iowa 2009, Grillo et al. 1999).   
 There are no vaccine regimens practiced for protection of rams against B. ovis in 
the United States.  New Zealand employs a commercially available vaccine and most 
applicable countries vaccinate young rams with B. melitensis Rev.1 (Iowa 2009, Jimenez 
et al. 1994).  Preliminary studies using mutant forms of the Rev.1 vaccine in sheep for 
protection to B. ovis challenge infection have been documented (Grillo et al. 2008).  The 
test and slaughter method is used commonly to rid herds of infection.  Antibiotic 
treatment has been attempted in valuable rams but generally is not feasible for treatment 
of a herd.  B. ovis is not infectious to humans and although potentially detrimental to the 
sheep industry, not considered a bioterrorist threat.   
 Brucella canis 
 
 Brucella canis was first described by Carmichael and Bruner in 1968 and is the 
cause of brucellosis in dogs and other canids.  The disease became of interest after a large 
number of abortions were noted in beagles in 1966 (Morisette 1969).  Geographically, 
cases of B. canis have been documented in the United States (particularly the southern 
states), Mexico, Canada, Central and South America, some European countries, Tunisia, 
Nigeria, Madagascar, Malaysia, India, Korea, Japan and China.  Brucella canis, like B. 
ovis, is a species of Brucella that has a naturally rough phenotype in its infectious form.   
 The primary host for B. canis is the canine, and both male and female animals are 
affected.  Transmission of the organism can be venereal or through contact of mucous 
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membranes with urine or with infectious tissues following an abortion.  Females have 
been shown to shed the bacterium in vaginal discharges for up to 6 weeks following an 
abortion.  Males have been shown to shed the bacteria sporadically for years after initial 
infection in semen and urine.  Live B. canis can also be found in milk, urine, saliva, nasal 
and ocular secretions, and feces of infected animals (Ledbetter et al. 2009, Wanke et al. 
2004).  Canine brucellosis is typically manifested as late-term abortions in females and 
sterility in males.  Seemingly healthy pups may be born congenitally infected and 
develop symptoms later in life (Iowa 2009).  In males, orchitis, epididymitis, scrotal 
edema, and sterility have been observed.  Other symptoms may include lymphadenitis, 
fatigue, loss of appetite, loss of alertness, and behavioral abnormalities.  Infected animals 
often do not appear outwardly ill but can remain infected for up to 5 years (Wanke et al. 
2004).   Canine brucellosis is rarely fatal.  Antibiotic treatment is available, although 
some forms of treatment are expensive while others are not always effectual.  The 
greatest economic impact of the disease is seen in breeding kennels, where up to 75% 
fewer puppies have been noted in some affected kennels (Iowa 2009).  There is no 
vaccine available for B. canis, and control is most often performed by removal of infected 
animals and sanitation of the kennel or living space previously occupied by the animal.   
 Human infection is rare and normally occurs in immunosuppressed individuals if 
contact of the mucosal membrane or abraded skin occurs with >1×106 organisms.  
Symptoms in people infected with B. canis are similar to those seen with other species of 
zoonotic Brucella.  Although it is a zoonotic pathogen, B. canis is not considered to be a 
potential agent of bioterrorism.    
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 Brucella neotomae and Other Proposed Brucella Species of Terrestrial Animals 
 
 Brucella neotomae was first described in 1957 after isolation from the desert 
wood rat in the United States by Stoenner and Lackman (Cameron and Meyer 1958).  
Brucella neotomae is a smooth organism, has a distinctive metabolic pattern, and 
performs similarly on biochemical tests used to identify other species of Brucella (Meyer 
1990). 
 Most recently, B. microti has been described as a Brucella species isolated from 
common voles in the Czech Republic and red foxes in lower Austria (Scholz et al. 2009).  
Another proposed species of Brucella is the newly described B. inopinata, which was 
isolated in Germany from a breast implant wound of a 71-year old woman.  B. inopinata 
is genetically highly homologous to other recognized Brucella strains but exhibits a 
unique 16S gene sequence (Scholz et al. 2009).  Studies on these new proposed strains 
are ongoing.  Further research is needed to determine their threat to agriculture or 
economy. 
 Brucella ceti and Brucella pinnipedialis  
 
 Brucella ceti and B. pinnipedialis have been recently described as the cause of 
brucellosis in marine mammals (Foster et al. 2007).  In 1990, a common dolphin from the 
English coast tested seropositive for anti-Brucella antibodies, sparking research into the 
field of marine mammal brucellosis worldwide (Jepson et al. 1997).  These two species 
were placed in the Brucella genus because they are aerobic, non-motile and catalase-
positive.  Furthermore, these species have a greater than 77% homology to other species 
in the genus Brucella (Foster et al. 2007).  Brucella ceti is the name given to the novel 
Brucella species causing brucellosis in cetaceans (such as whales, dolphins, and 
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porpoises).  Brucella pinnipedialis is the name given to the novel Brucella species 
causing brucellosis in pinnipeds (such as seals, sea lions, and walruses).  Brucella strains 
have also been isolated from several marine mammals, including common seals, 
porpoises, common dolphins, bottlenose dolphins, white sided dolphins, striped dolphins, 
minke whales, Pacific harbour seals, ringed seals, harp seals, and European otters 
(Forester et al. 2007).  Symptoms vary from asymptomatic to observed cases of orchitis, 
abortion, and meningeoenephalitis (MacDonald et al. 2006). 
 Human infection has also been reported in individuals working closely with 
marine mammals (Brew et al. 1999).  It is reported that brucellosis in humans from 
marine mammals is similar to the disease contracted from terrestrial animals with 
symptoms including headaches, malaise, severe sinusitis, seizures and spinal 
osteomyelitis (MacDonald et al. 2006).  As these species are a new area of research, more 
studies must be performed to determine their ultimate threat to public health.   
Human Brucellosis 
 
 Brucellosis in humans is a disease that has the potential to affect several systems 
with symptoms ranging from mild to severe.  Transmission is normally from infected 
animals.  Incubation periods may vary from weeks to several months before symptoms 
fully develop (Franco et al. 2007).  Infected individuals may experience undulating fever, 
fatigue, and headaches, as well as joint and back pain.  These symptoms may have long-
term or chronic effects in some patients.  More serious symptoms are observed in cases 
where the bacterium has migrated to the central nervous system or endocardium, in which 
case meningitis, endocarditis and psychoneurosis can occur (Franco et al. 2007, Alapin 
1976, Harris et al. 1954).  Although brucellosis is not typically considered a fatal disease, 
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human cases left untreated can result in mortality (Park et al. 2007, Franco et al. 2007).  It 
is believed that many cases of human brucellosis remain undiagnosed and thus 
unreported.  This may be due to the similarity of initial symptoms to those of influenza 
(Chain et al. 2005).  
 Human brucellosis is diagnosed using serological testing and by culturing bacteria 
from blood, lymph, or cerebrospinal fluid (Seleem 2009).  Disadvantages of this method 
include the slow growth of Brucella in culture and a potentially low number of colony 
forming units (CFU) present in clinical samples due to the stage of infection or to the use 
of antibiotics prior to sample collection (Seleem 2009, Franco et al. 2007).  The Rose 
Bengal test is also useful for human diagnosis, as well as specially designed ELISAs 
(Acha et al. 2003, Orduna et al. 2000).  The tube agglutination test was the first test used 
for diagnosis of brucellosis in humans and was later adapted for use in animals.  In this 
test, sera is diluted and added to a tube containing a standard quantity of killed Brucella 
cells.  The occurrence of clearing and agglutination following incubation is considered a 
positive result (Beran 1994).  Wright’s serum agglutination test, which measures the titer 
of anti-brucella antibodies (Mert et al. 2003), and Huddleson’s slide agglutination test, in 
which serum agglutination can be rapidly detected (Spink 1956), are successful 
diagnostic tools for brucellosis. Studies surrounding the use of molecular-based diagnosis 
using the Polymerase Chain Reaction (PCR) have also been explored with varied results 
(Kattar et al. 2007).  It is also crucial to obtain a detailed case history of any travels to 
endemic countries or ingestion of any untreated animal products imported from endemic 
countries. 
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 Treatment for human brucellosis is most commonly through combined antibiotic 
regimens, as treatments using single antibiotics have shown higher relapse rates (Pappas 
et al. 2005 & 2006, Solera et al. 1997).  The recommended combination is doxycycline 
coupled with rifampin, but doxycycline with streptomycin or gentamicin have also been 
effective treatments (Seleem 2009, Solera et al. 1997).  Prior to 1986, the World Health 
Organization (WHO) reported that a doxycycline-streptomycin regimen was the preferred 
method of treatment for brucellosis in human adults.  Currently, however, the WHO 
Committee on Brucellosis has updated their recommendation to a combined oral 
treatment of 600-900 mg of rifampicin daily coupled with 200mg/day of doxycycline for 
a period of 6 weeks for the treatment of acute brucellosis in human adults (WHO 2004).  
Regardless of therapeutic regimen used, relapse rates of approximately 5-10% have been 
observed in both adults and children treated for brucellosis (Hall 1990). 
Caprine Model for Brucellosis 
 
 The goat serves as the primary host for B. melitensis, which is the most 
pathogenic species in humans, and as a secondary host for B. abortus, which produces 
clinical symptoms similar to those observed in cattle.  Because both species pose a threat 
to public health and agriculture, the development of new and more efficient vaccines are 
an important area of research.  There is no single vaccine effective against both species 
that is safe to use at any stage of gestation (Elzer et al. 2002).  Some commonly used 
vaccines, such as S19 and Rev.1, conflict with serological diagnosis, becoming an 
obstacle for efforts to eradicate the disease.  The development of a caprine model for the 
study of improved vaccine candidates and other genetic mutants was proposed by Elzer et 
al.. in 2002.   
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 The use of the caprine model was a logical choice for the study of modified 
Brucella strains.  As compared to the commonly used murine model, the goat is a natural 
ruminant host (Elzer 2002).  The goat model is also advantageous over the bovine model 
due to its lower cost and decreased gestation periods.  Furthermore, these attributes allow 
larger cohort sizes for increased statistical significance (Elzer et al. 2002).  The model 
focuses first on bacterial colonization, monitoring of both pregnant and non-pregnant 
female animals, as well as the fetus and kid, following conjuctival administration.  The 
colonization assay is performed using various tissue samples obtained at necropsy for 
bacteriological and serological analysis (Elzer et al. 2002).   In this way, the propagation 
of the pathogen throughout the animal can be monitored.  A pathogenicity assay was 
developed to study the colonization capability of experimental mutants on the dam and 
subsequently the fetus (Elzer et al. 2002).  To test vaccine efficacy, a third assay was 
developed using non-pregnant females given an experimental vaccine followed by 
impregnation and a challenge infection at approximately 110 days gestation with virulent 
B. melitensis 16M and/or B. abortus 2308 (Elzer et al. 2002). 
 Brucella  melitensis in the Caprine Host 
 B. melitensis infects the goat as its primary host and can be quickly transmitted 
from infected dams via vaginal discharges, fetal fluids, placenta, and the fetus itself.   
Goats are capable of shedding the bacterium for 2-3 months post-parturition in vaginal 
discharges.  There is also long-term shedding observed in milk (Iowa State University, 
2009).  The usual route of infection is through contact of any of these infectious tissues 
with mucous membranes.   The outcome of exposure varies dependant on the age and 
health condition of the animal as well as the number of invading bacteria (Alton 1990). 
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 Once infected, animals may experience abortions in pregnant females and 
impaired fertility in males.  Non-pregnant animals are often asymptomatic (Iowa 2009).  
It has been observed that abortions occur in 70-100% of infected pregnant females; and 
of those, 90-100% of the dam/kid pairs are found to be culture positive (Elzer et al. 
2002).  Kids that are not aborted are normally weak at birth and found to be colonized 
with B. melitensis.  Elimination of the infection is most easily accomplished by slaughter 
of the herd (Merck 2006, Alton 1990). 
 Brucella abortus in the Caprine Host 
 
 The primary hosts for B. abortus are cattle, but an infection in goats (a secondary 
host) resembles bovine brucellosis in clinical symptoms and provides a model for the 
study of B. abortus in cattle (Anderson et al. 1986, Meador et al. 1986 & 1989, Elzer 
2002).  Abortion and colonization are not as prevalent in caprine B. abortus infections 
with an approximately 30-50% abortion rate in infected females and a 50-70% 
colonization rate in dam/kid pairs (Elzer et al. 2002).  It has been observed that both 
nursing and non-nursing females shed the bacterium, but non-nursing females tend to 
have higher concentrations of B. abortus in their milk (Meador et al. 1986).  The 
colostrum of infected animals tested positive for anti-brucella antibodies, which have 
been shown to pass to previously antibody-negative neonatal kids following colostral 
intake (Meador et al. 1986 & 1989).    
 The serological and clinical pattern observed in the caprine host due to B. abortus 
infection is sufficient for the study of B. abortus-derived vaccines in the goat model.  
Serologically, B. abortus RB51 does not revert from a rough to smooth phenotype in the 
goat, does not promote the formation of anti-OPS antibodies that may interfere with 
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diagnostic tests, and is capable of inducing the production of anti-Brucella antibodies to 
rough antigens (Shurig et al. 1991, Roop et al. 1991).  Clinically, RB51 does not induce 
abortions in the caprine host when fetuses are injected during the final 50 days of 
gestation (Roop et al. 1991).  RB51 is cleared rapidly from the caprine and ovine host, 
showing a marked reduction in virulence and survivability when compared to Rev.1 in 
the these animals.  Thus, commercial RB51 has been shown to provide inadequate 
protection in the caprine and ovine hosts against B. melitensis challenge (Adone et al. 
2005, Neilson et al. 2004).   
Brucella Vaccines 
 
 Vaccination against bovine brucellosis, a disease caused by B. abortus, is a 
powerful tool in the effort to eradicate the disease in the United States.  The first 
brucellosis vaccine approved for field use by the US government, smooth B. abortus 
Strain 19 (S19), was approved and implemented in 1941 (Neilson et al. 1990).  Conflicts 
with S19 arose with diagnostic testing and a new rough vaccine, B. abortus RB51 
(RB51), was approved by the USDA to replace S19 as the standard brucellosis vaccine in 
1996 (USDA 1996).  Although RB51 resolved the problems presented by S19 with 
diagnostic testing, the popular opinion of RB51 is that it may be a less efficacious 
vaccine than S19.  The immunogenic differences between S19 and RB51 are principally a 
manifestation of differences in structure, function, and survivability in the host. 
 The responses of the host’s immune system to a typical infective strain of B. 
abortus include both cell-mediated and humoral reactions.  The humoral reactions are 
those involving the production and function of antibodies that target the surface 
components of the cell’s outer membrane and complement.  Studies on the role of 
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complement have shown it to be ineffective in combating B. abortus directly, but it may 
aid in phagocytosis (Timoney et al. 1998)( Barquero-Calvo et al. 1997). The primary 
immunogenic component of the smooth outer membrane is the O-polysaccharide (OPS) 
component of the lipopolysaccharide (LPS).  The antibody response to the OPS mediated 
by the host is ineffective in providing protective immunity against a challenge infection 
as shown through effectiveness of the rough RB51 vaccine strain. In fact, the presence of 
IgG1 antibodies predominantly produced in response to B. abortus does not correlate to 
elimination of the pathogen (Bellaire et al. 2005).  However, opsonic antibodies can 
promote intracellular killing and slow the reproduction rate of intracellular B. abortus, 
but antibodies alone are not effective in clearing the pathogen from the host (Timoney et 
al. 1998, Arenas et al. 2000, Bellaire et al. 2005).  In terms of vaccination, the cell-
mediated immune response is primarily responsible for protective immunity. 
 The cell-mediated immune response to B. abortus is primarily mediated by 
activation of phagocytes and T-cells of the adaptive immune response.  The role of cell-
mediated immunity is to identify and destroy host cells housing harmful intracellular 
pathogens, such as viruses and facultative or obligate intracellular bacteria (Abbas 2005).  
For B. abortus, the macrophage is primarily responsible for ingestion and clearance of the 
pathogen from the extracellular environment.  Macrophages that are not activated prior to 
ingestion of B. abortus differ in their interaction with the pathogen than do previously 
activated macrophages, which are considerably more brucellacidal (Barquero-Calvo et al. 
2007, Elzer 2007).  Antigen presentation to both CD4 and CD8 T-cells is a key 
occurrence in the host’s development of protective immunity.  B. abortus ingested by 
inactivated macrophages can inhibit development of the phagolysosome or neutralize the 
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acidic environment therein, avoid killing, and eventually replicate within the cell 
relatively undetected (Barquero-Calvo et al. 2007).  In these inactivated phagocytes, the 
pathogen causes the macrophages to become immunosuppressive against a strong CD4+ 
Th1 response (Forestier et al. 2000).  However, previously activated , or immune, 
macrophages degrade B. abortus upon ingestion and phagolysosomal fusion, where it can 
be recognized and presented to CD4+ Th1 cells by the MHCII receptor.  An effector 
CD4+ Th1 cell further activates macrophages by secreting IFNγ, which triggers an 
increase in antimicrobial activities against the pathogen.  Likewise, B.abortus elicits a 
strong CD8+ T cell response, which mediates cytotoxic activity and functions to lyse 
infected cells.   If a macrophage that houses replicating B. abortus cells is lysed, the 
pathogen is released into the extracellular environment, where it can either infect other 
cells or become ingested and destroyed by activated macrophages (Elzer 2007, Baldwin 
and Winter 1994, Jones 1992, Araya et al. 1989). 
 Brucella abortus S19 
 
 The S19 vaccine strain was developed in 1923 by Dr. John Buck and was shown 
to produce adequate immunogenicity in guinea pigs without causing detrimental 
pathology.  Dr. Buck found that S19 was similarly effective in cows against challenge 
infections when given in the correct dose.  Statistically, S19 provides 70-90% protection 
in pregnant heifers in preventing abortion and infection (Nicoletti 1990).  This attenuated 
strain was created by isolating a virulent B. abortus strain from an infected animal which 
was then serially-passaged and allowed to incubate at room temperature for several 
months.   When examined, Dr. Buck found the isolate to be attenuated (Graves 1943).  
However, it has also been observed that S19 may cause abortions in pregnant cows, 
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orchitis in bulls, pyrexia, and other infections in some cases (Nicoletti 1990).  Human 
infections have also been reported through accidental vaccination or exposure (Wallach 
et al. 2008).  Antibodies to S19 can be passed from cow to calf through the colostrum 
following birth.  If calves are vaccinated during this period, these maternal antibodies are 
capable of neutralizing or killing S19.  Vaccination of cattle herds is typically performed 
in 3 to 6 month old heifers at a standard dose of 5×1010 to 8×1010  CFU (OIE 2009, 
Poester et al. 2006). 
 The immunologic response to S19 is similar to that of an infectious strain of B. 
abortus, but does not result in a full infection (Nielson et al. 1990).  S19 is a smooth 
strain of B. abortus and expresses a fully intact and functional LPS with the OPS on the 
surface of the outer membrane.  Because the OPS is a primary immunoantigen, S19 is 
capable of inducing the production of OPS-specific antibodies in the host, stimulating 
both cell-mediated and humoral immunity.  However, this feature of S19 is problematic 
since standard diagnostic tests detect the presence of anti-OPS immunoglobins as a false-
positive reaction.  Typically, S19 will provide protection against virulent B. abortus for 
several years while the presence of anti-OPS antibodies will decrease within months of 
vaccination.  However, it has been observed that some animals become infected 
permanently with S19 following vaccination, continuing to produce anti-OPS antibodies 
for years following vaccination (Jacob et al. 2005).  For these chronic shedders, serologic 
tests will constantly provide positive results for vaccinated animals that are uninfected.   
  Because of this issue, a new vaccine, named RB51, was licensed in 1996 that was 
a rough strain of B. abortus 2308 (USDA 1996).  Because RB51 lacks the OPS found on 
virulent strains of B. abortus as well as on the S19 vaccine strain, the problem with 
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diagnostic tests was solved. RB51 does not promote the production of anti-OPS 
antibodies in a strong humoral response, yet is effective in providing adequate protection 
against challenge infections (Poester et al. 2006).   
 B. abortus RB51  
 
 The current U.S. vaccine used to protect cattle against bovine brucellosis is the B. 
abortus RB51 vaccine strain.  RB51 was developed by making serial-passages of B. 
abortus 2308 on rifampicin and penicillin supplemented Tryptic soy agar (TSA) plates 
(Schurig et al. 1991).  The resultant RB51 strain was rifampicin-resistant and lacked the 
OPS of the original smooth 2308 strain.  Genetically, this is due to a defect in the LPS 
biosynthesis loci (Vemulapalli et al. 2004).  Although there was concern surrounding the 
release of an antibiotic-resistant strain of B. abortus, in February of 1996 the United 
States designated RB51 as the premier vaccine, replacing the Strain 19 vaccine used prior 
to this switch (Poester et al. 2006).   
 RB51, which lacks the O-polysaccharide chain normally found on strain 19 and 
wild-type Brucella abortus, does not initiate the production of smooth OPS antibodies in 
the vaccinated animal.  Thus, RB51, unlike strain 19, does not produce a positive test 
result for an animal that is negative for brucellosis but has been exposed to B. abortus 
through vaccination.  It has also been shown that RB51 does not revert to a smooth 
phenotype when administered.  RB51 has also been shown to be equally efficacious as 
strain 19, but is less abortigenic and does not produce any symptoms of disease after 
vaccination (Poester et al. 2006) (Perry 2005).  RB51 does not produce a very strong 
antibody reaction in the vaccinated animal but it does cause a cell-mediated response that 
is the primary factor in protecting the animal from a full infection (Poester et al. 2006).  
 27
Studies have shown that RB51 is 70-90% effective in preventing abortions and disease in 
cattle tested (Stevens et al. 1995) (USDA 1996).  Currently, RB51 remains the principal 
vaccine for bovine brucellosis at this time and an important component of the State-
Federal Brucellosis Eradication Program.  Domestic calves are vaccinated with RB51 at 4 
to 12 months of age at a dosage of 1.0-3.4x1010 CFU and tagged appropriately (USDA 
1996, Poester et al. 2006).  Following vaccination, RB51 is quickly cleared from the 
draining lymph nodes (Chevelle et al. 1992 & 1993).  Over the course of a typical 
vaccination with live attenuated RB51, the organism is typically cleared from cattle in 6 
to 8 weeks.  RB51 is usually undetectable in the blood stream within a period of 3 days 
and are not present in mucosal secretions (USDA 1996).  Both subcutaneous and 
conjunctival administrations of RB51 have been proven effective in conferring protection 
against challenge infections of B. abortus (Jiménez de Bagüés et al. 1994, Stevens et al. 
1996), and experiments focused on oral vaccination have yielded promising results (Elzer 
et al. 1998).   
  Brucella melitensis Rev.1 
 
 The Rev.1 vaccine was developed in 1957 by Elberg and Herzberg for the 
protection of goats and sheep against B. melitensis and is a streptomycin-non-dependent 
reverse mutant of the streptomycin-dependent B. melitensis 5056, a virulent strain 
(Sanmartino 2005).  Low virulence has been observed in small ruminants when the 
vaccine is administered under standard conditions.  Furthermore, upon continued 
passage, Rev. 1 does not revert to a pathogenic form (Diaz-Aparicio 2004).  Similarly to 
S19, Rev-1 is a smooth strain with an intact OPS.  Thus, Rev.1 vaccinated animals 
produce antibodies identical to animals naturally infected with wild-type Brucella, which 
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may produce false positive results using standard serological tests.   
  When administered to pregnant animals, Rev.1 has been shown to be abortigenic 
at standard vaccination doses.  It is also found that a reduced dosage of Rev.1 does not 
fully prevent the induction of abortion and does not confer full protection against B. 
melitensis infections in both goats and sheep (Gonzalez et al. 2008, Blasco 1997).  
Because of the pathogenicity issues when administered to pregnant animals, there is no 
completely safe strategy for vaccination using Rev.1.  Conjunctival vaccination of sheep 
during lambing season or late lactation has been suggested as an optimal vaccination 
strategy for adequate protection with a reduced frequency of abortion (Blasco 1997). 
 The recommended vaccination method for Rev.1 is to use a standard dose (1x109 
to 2x109 CFU) subcutaneously injected for female goats and sheep at the age of 4 to 6 
months old.  Following vaccination, Rev.1 causes infection in the animal for a period of 3 
months, with colonization generally restricted to the lymph nodes and spleen. The 
organism has also been located intracellularly in the dendritic follicular cells and 
macrophages of the draining lymph nodes following vaccination (Munoz 2008).  Strain 
persistence has also been reported due to horizontal spread among vaccinated herds 
(Banai 2002, Bardenstein et al. 2002). Rev.1 induces a potent antibody response, which 
poses an obstacle to diagnostic serological tests (Blasco 2006).  Reduced serological 
responses have been observed in animals administered Rev.1 through conjunctival 
vaccination, as opposed to subcutaneous injection.   
  Other Vaccine Research 
 
 In attempts to increase the safety of vaccination, studies to develop a vaccine that 
is protective and non-pathogenic in animals, as well as non-infectious to humans were 
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conducted.   Vaccines produced from killed field isolates and laboratory strains have met 
with mixed reviews.  Although some vaccine candidates decreased pathogenicity, 
protection provided was inadequate (Schurig 2002).  Furthermore, in killed vaccines 
using smooth strains of Brucella, positive serology poses a problem to detection 
capabilities using standard diagnostic tests. Vaccines developed using antigenic fractions 
of Brucella cells, including portions of the Brucella cellular envelope, outer membrane 
proteins, and LPS fractions, among other proteins, have been tested.  Some vaccines 
utilizing antigenic fractions, when administered using an immunogenic adjuvant, have 
provided immunity in laboratory tests (Shurig 2002).  DNA vaccine research for 
brucellosis is limited to small laboratory animals and has not been examined for use in 
natural hosts.  In these studies, the level of protection provided by DNA vaccines is 
inferior when compared to the live-attenuated vaccines currently in use (Schurig 2002).  
Nevertheless, there is no killed or sub-unit Brucella vaccine approved for commercial 
use. 
 Human vaccine trials 
 There is no vaccine against any species of Brucella that is safe for human use.  
The vaccines previously described for use in animals are infectious to humans, and some 
carry antibiotic resistance genes that are a cause of concern when considering treatment 
methods.  In developing countries in which brucellosis is rampant, human vaccine trials 
have been performed with little success.  Attenuated live vaccine strains administered to 
humans show varied protective capabilities and adverse side-effects.  Human vaccine 
trials using sub-unit brucellosis vaccines also provide varied results (Schurig 2002).  The 
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development of a vaccine for human use in countries where the disease has been 
eradicated is also of interest considering the status of brucellosis as a bioterrorist threat.   
It is generally accepted, however, that the best prevention technique for brucellosis in 
humans is through eradication of the disease in animals and proper treatment of food 
products intended for human consumption. 
Brucella Genomic Studies 
 
 There are currently ten fully sequenced Brucella strain genomes available from 
five species of Brucellae (B. abortus, B. melitensis, B. suis, B. ovis, and B. canis).  
Twenty five additional Brucellae genomes are also in the progress of being sequenced 
(Seleem et al. 2009).  Complete genomic sequences allow researchers the opportunity to 
study and manipulate genes of Brucella spp. and their protein products in order to learn 
more about the functional aspects of virulence, replication, and survival of this organism, 
both in and out of the host.   Not only does this provide insight into the genetic coding 
sequences unique to brucellae, but it also facilitates the studies of conserved coding 
sequences and their comparative functions across several species of bacterial pathogens.  
Genomic studies have also facilitated proteomic studies to identify proteins involved in 
virulence, pathogenicity, and host specificity.  Expanding genomic data has provided new 
perspectives into the examination of the Brucella genus as a whole, as well as 
comparative studies between Brucella species.  Manipulation of the Brucella genome has 
permitted the determination of the function of several genes.  Genes involved in host 
specificity, survival, and virulence are frequently targeted in efforts to improve 
vaccination.  Techniques such as genetic transformation or gene disruption in Brucella 
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spp. are widely used to study specific genes with successful results (Zygmunt et al. 
2006).   
 Molecular transformation is a method in which the natural characteristics of an 
organism can be manipulated by altering its genetic repertoire.  This technique has been 
used frequently in the study of genetic complementation in brucellae.  Methodology 
includes the construction of a plasmid vector containing a selective marker and the gene 
region of interest, transformation of the vector into the cell, and selection of genetically 
modified cells.  The pBBR1MCS plasmid is a broad-host-range vector that is stably 
maintained in Brucella species, under both in vivo and in vitro conditions (Elzer et al. 
1995).  The vector is retained at a low copy number within the cell, but is not integrated 
into the genome (Kovach et al. 1995, Elzer  et al. 1995).  Variations of the pBBR1MCS 
plasmid contain different selectable markers used for the identification of effectively 
modified organisms. 
 Other methods frequently used in genetic manipulation include Gateway-based 
destination vectors and gene disruption or deletion.  The Gateway recombination cloning 
system is used to move genes into a multiple vector system for functional analysis and 
protein expression without the use of the restriction endonucleases and ligases used in 
traditional cloning methods (Invitrogen 2003).  This system has been used to identify and 
study open reading frames of B. melitensis and B. abortus at a proteomic level to 
determine biological function (Dricot et al. 2004, Hallez et al. 2007).   
 Suicide vectors, also known as gene-replacement plasmids, are utilized for site-
directed chromosomal insertion by homologous recombination between homologous 
DNA sequences.  The vector itself does not replicate and is not maintained in the cell 
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(Elzer et al. 1995).  Gene-replacement plasmids are introduced via electroporation or 
chemical treatment into the cell, similar to the methodology described previously. The 
goal is to replace a target gene of interest within the genome with a gene from the vector, 
most often carrying a selectable marker for the detection of modified cells (Sherratt 
1995).  The marker present on the vector is flanked with sequences homologous to those 
flanking the wildtype gene of interest within the genome.  After introduction into the cell, 
the wildtype gene of interest is disrupted, following a double-crossover homologous 
recombination event which incorporates the selectable marker into the genome (Sherratt 
1995).  This method is a form of site-directed mutagenesis. 
 Another method of gene disruption is through transposon mutagenesis.  This 
technique uses random gene inactivation to identify cellular functions associated with 
virulence and survival (Wu et al. 2006).  This form of mutagenesis allows the random 
transference of genes, most often selectable markers, into the chromosome of a host 
organism using transposable elements, potentially disrupting the wildtype gene located at 
the insertion site.  A pool is created from those mutants selected to have taken up the 
selective gene carried by the transposon.  This mutant pool is then introduced into a host 
animal and analyzed for reductions in virulence as compared to the wildtype strain.  This 
method of mutagenesis is randomized and not directed to specific genes.   
 Gene disruption or deletion mutants obtained using the methods above are 
analyzed in vivo with regard to reduced survival and intracellular replication to determine 
the function of the particular gene in question.  Studies in Brucella species using gene 
disruption or deletion mutants have proven successful in examining specific genes of 
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interest (Halling et al. 1991, Tatum et al. 1993, Drazek et al. 1995, Edmonds et al. 2001 
& 2002, Wu et al. 2006).   
Hemagglutinins 
 
 Blood agglutinins are produced by many pathogens, including bacteria, viruses, 
parasites, and plants (Nelson et al. 2006).  Much of the current research performed on 
pathologic hemagglutination is focused on viral hemagglutinins, namely the influenza 
virus.  There are two primary functions of viral hemagglutinins in infection: to recognize 
the host cell via sialic acid-associated receptors and to facilitate entry of the viral genome 
into the target host cell (Gambrian et al. 2006, Suzuki 2005, White et al. 1997). 
 In historical studies conducted under in vitro conditions, it was discovered that 
some bacteria produce proteins that promote the agglutination of red blood cells (Netter 
et al. 1954).   The bacterial hemagglutinin has been proposed to function in adherence of 
the organism to the surface of host cells (Alam et al. 1997).  Direct bacterial 
hemagglutination occurs when the protein hemagglutinin itself causes the agglutination 
of erythrocytes (Neter et al. 1954).  This was first described by Kraus and Ludwig in 
1902 (Koransky et al. 1975).  Indirect hemagglutination occurs when the bacteria 
increase the liability of the RBC to agglutination by antibodies by bringing about a 
physiological change in the surface properties of the erythrocyte (Neter et al. 1965).   
 Although many proteins have been studied as hemagglutinins, the 
lipopolysaccharide (LPS) has been the focus of many bacterial hemagglutination 
experiments (Alam et al. 1997, Watkins et al. 1987).  The LPS of Brucella species serves 
several functions in virulence and survival of the pathogen, yet rough strains are also 
capable of virulence and survival in vivo.  Furthermore, there is no data that shows the 
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Brucella LPS as being involved in invasion of the host cell (Rocha et al. 1999, Aragon et 
al. 1996).  However, there is data that shows an increased rate of adherence and uptake 
into host cells for rough strains of Brucella as compared to smooth strains, yet rough 
strains were not as efficient to replicate within the host cells (Ferrero et al. 2009).  This 
suggests an adherence mechanism separate from the LPS.  The mechanisms concerning 
the association of Brucella to host epithelial cells, RBCs or the effector molecules 
involved in cellular uptake are not clearly understood.  Since cellular adherence is 
necessary for uptake of facultative intracellular pathogens, it is important to understand 
the mechanisms and molecules involved in this process.  Many studies have been 
performed to identify and characterize virulence factors produced by Brucella species 
that are associated with the attachment and invasion of host cells, yet exact mechanisms 
remain unclear (Rosetti et al. 2009, Ferrero et al. 2009, Castaneda-Roldan et al. 2006 & 
2004, Rocha et al. 2002 & 1999, Guzman-Verri et al. 2001, Zaitseva et al. 1996, Eskra et 
al. 1991, Hoffman et al. 1990, Vendrell et al. 1990). 
 An increase in the identification and study of virulence genes for Brucella species 
has occurred since the mapping of several Brucella genomes.  In 2002, DelVecchio et al. 
described a gene coding for a putative hemagglutinin (GI:17989062) found in the 
genomic sequences of B. melitensis and B. ovis (DelVecchio et al. 2002a &2002b).  A 
highly homologous but not identical gene sequence is also found in B. suis and B. canis.  
Other matches with some homology to the B. melitensis putative hemagglutinin gene are 
as follows:  a B. ovis hemagglutinin (GI:148558421); a B. melitensis glycoprotein X 
precursor (GI:225686341); a cell wall protein AWA1 precursor in B. suis 
(GI:254702929), B. canis (GI:161620616), B. ceti (GI:254715437), and B. pinnipedialis 
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(GI:254708522); and a putative cell wall surface protein of B. ovis (GI:148558357) and 
B. suis (GI:23500299).  The gene is not naturally found in any strain or subspecies of B. 
abortus. 
 Previous studies were performed on suspected Brucella hemagglutinins and their 
agglutinative properties on human and animal erythrocytes.  It was shown that B. abortus 
2308 has a significantly lower titer using the hemagglutination test, as described by 
Evans et al. (1980), than B. melitensis 16M.  Furthermore, the previously described B. 
melitensis hemagglutinin (GI:17989062) was investigated in the caprine model.  The 
gene was placed into B. abortus 2308 via the pBBR1MCS-4 plasmid (tagged 2308-QAE) 
and a gene deletion B. melitensis 16M mutant was also created.  The B. abortus 2308-
QAE strain showed increased virulence (as compared to B. abortus wild-type) in 
colonization and pathogenicity studies, similar to the results in the B. melitensis 16M 
challenge animals.  The 16M deletion mutant showed no signs of attenuation in 
colonization of a caprine host, but the pregnant animals that received the deletion mutant 
showed a 30% reduction in abortions when compared to the parent B. melitensis strain.  It 
was concluded that the specific QAE gene was a putative hemagglutinin and virulence 
factor of B. melitensis, as well as a possible host specificity factor for the caprine host 
(Perry 2007).   
Protein Characterization 
 Identification of protein characteristics is an integral part of learning the 
functional aspects of a protein as well as the role it plays in cellular activity and survival 
as a whole.  Protein expression and function may vary depending on in vivo or in vitro 
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conditions, making it necessary to examine both avenues in characterization of the same 
protein.   
 For assessment of protein expression in vivo, cellular activity inside of a living 
animal host is examined.  The identification of protein-specific antibodies using western 
immunoblot techniques and absorption assays are useful in determining the relative size 
and antigenicity of a specific protein.  Antibody absorption assays examine immune sera 
by combinination with lysates of the in vitro-grown pathogen to identify antibodies 
specific for proteins exclusive to expression in vivo by removal of cross-reacting 
antibodies (Handfield et al. 2000).  Specifically, the serum of an animal that has been 
exposed to a protein of interest via infection or vaccination and, in theory, contains in 
vivo-produced, protein-specific antibodies is mixed with lysates from cells lacking the 
gene for the protein of interest, but otherwise identical to the in vivo strain.  This step 
serves to remove any cross-reacting antibodies in the serum (Handfield et al. 2000, 
Rollins et al. 2005).  Next, the absorbed serum can be subjected to analysis by western 
immunoblot containing cellular lysates of both the in vivo strain and the strain used for 
absorption.  Following identification by secondary antibody conjugation and blot 
development, coupling of in vivo- produced antibodies to the protein of interest can be 
analyzed to gain further information on the specific protein.  This type of antibody 
absorption assay is useful if the in vivo expressed protein of interest is sufficiently 
antigenic to induce the production of antibodies adequate for detection using western 
immunoblot (Handfield et al. 2000, Rollins et al. 2005).  Specifically, this assay is most 
useful in the examination of externally exposed or secreted proteins. 
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 For examination of proteins in vitro, cells are grown outside of an animal host in 
or on laboratory-made media.  There are numerous tests available to examine proteins 
produced under in vitro conditions.   Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and 2D gel electrophoresis followed by mass spectrometry 
analysis are commonly used for the characterization of such proteins.   
 SDS-PAGE is a commonly used biochemical technique used to separate proteins 
based on molecular weight.  Proteins are separated on a polyacrylamide gel via 
electrophoresis, during which an electric current is applied to the gel, causing negatively 
charged proteins to migrate at different rates depending on the size of each protein 
(Shapiro et al. 1967).  Following protein separation via electrophoresis, the gel is stained 
for visualization of the separated proteins.  A common stain, Coomassie brilliant blue, is 
commonly used due to its exceptional sensitivity to protein binding (Merril 1990).  Once 
stained, the separated proteins can then be examined based on molecular weight. 
 Analysis using 2D gel electrophoresis is a technique that separates proteins on 
two dimensions:  molecular weight and isoelectric point.  This technique provides a 
greater degree of protein separation than SDS-PAGE.  2D gel electrophoresis is also 
considered to be the most sensitive procedure for the analysis of low abundance proteins 
(Berth et al. 2007).  This technique is commonly used to identify unique proteins between 
two strains of highly homologous organisms.  To achieve this, lysates from each strain 
are subjected to 2D gel electrophoresis and examined, following staining, to locate any 
unique proteins not shared by both strains.  Further characterization of these unique 
proteins can be assessed by mass spectrometry analysis, during which proteins are 
ionized and introduced to a mass analyzer (Hernandez et al. 2006, Zhang et al. 1994).  
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Proteins can be identified based on amino acid sequence and protein quantity can be 
assessed. 
Polymerase Chain Reaction 
 The Polymerase Chain Reaction (PCR) is a method used to amplify specific 
regions of DNA from a large amount of diverse sequence for the purpose of visualization 
and identification.  PCR is widely applied in many different fields of science including 
biochemistry, molecular biology, genetics, medicine and forensics. Because of the 
sensitive nature of PCR, the workspace and technique must be both sterile and precise for 
the prevention of contamination.  However, there are several inhibiting factors for PCR in 
even the most sterile conditions.  PCR is currently being studied as a possible detection 
method for brucellae in bodily fluids such as blood and urine (Navarro et al. 2006, 
Queipo-Ortuno et al. 2006, Zerva et al. 2001, Morata et al. 1999, Yagupsky 1999).  
Currently, there is no accepted standard for detection of brucellae using PCR and 
detection is most often accomplished using tissue and blood cultures.  
 The current method of diagnosing brucellosis involves culturing the organism 
from the blood, bone marrow or tissues or testing the animal for the presence of anti-OPS 
antibodies (Yagupsky 1999).  A standing problem with culture, most often from the 
blood,  is that Brucella are very slow growing organisms and several days are needed for 
a positive confirmation, which can delay treatment.  Standard diagnostic testing using 
antibody recognition is also problematic due to false positives caused by Y. enterocolitica 
0:9 infections and smooth vaccine strains.  In endemic countries where brucellosis is a 
serious threat to public health, the development of a more rapid yet still reliable method 
for diagnosis would greatly detection and treatment methods.  A PCR technique for the 
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detection of Brucella species has many advantages over current methods.  The PCR 
technique itself is fairly easy to perform, affordable, and data can be acquired in less than 
one day.  Other advantages include the targeting of brucella-specific DNA and the 
independence of antibody-based testing, which largely reduce the potential for cross-
reaction-based false positive results.   
 Currently, there is no standardized method for diagnosis of brucellosis using PCR 
and detection capabilities have varied between labs (Elfaki et al. 2005, Navarro et al. 
2004, Bricker 2002).  Some studies have shown that diagnosis using PCR techniques 
have had equal or better detection capabilities as blood culture, yet provided results in 
only hours, as compared to days for culture (Navarro et al. 2006, Queipo-Ortuno et al. 
2006, 2005 & 1997, Zerva et al. 2001, Morata et al. 1999).  Conversely, there have also 
been studies in which PCR techniques have provided inferior detection capabilities in 
comparison with culture techniques (Maas et al. 2007, Kattar et al. 2007, Navarro et al. 
2004 & 1999).  Reasons for inconsistent results may lie in inconsistencies involving 
techniques used among labs and in the variability of fluids tested.  Many labs perform 
PCR tests using whole blood cultures, however the heme-components found in whole 
blood can inhibit PCR amplification.  To circumvent this issue studies using serum were 
evaluated, but were ineffectual in some cases if the patient tested was not bacteremic at 
the time the sample was taken.  Urine has also been tested, yet only two Brucella species 
are shed in urine and neither is a threat to human health.  Other inconsistencies were 
found in the extraction of DNA using either manual DNA preparation versus the use of 
different commercially available kits, periodic testing versus one-shot testing, and 
differences in primers used.  The most commonly used primer in PCR detection studies 
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was developed by Baily et al. in 1992 for the detection of B. melitensis and B. abortus 
(Baily et al. 1992).  While successful trials have been reported in the use of the Baily 
primers, other primers are also of interest in PCR techniques for Brucella detection.  Of 
note are the AMOS primers developed by Bricker et al., which are capable of 
differentiating strains of B. abortus, B. melitensis, B. ovis, and B. suis by conventional 
PCR and gel electrophoresis (Bricker et al. 1994).  Studies using the AMOS primers have 
provided promising results (Bricker et al. 2003, 1995).  In some cases, the inability to 
reproduce previously successful PCR techniques by other labs has been noted (Navarro et 
































 The hypothesis for this study is that region E putative protein is a cell-surface 
hemagglutinin and host specificity factor that, when expressed in trans through B. 
abortus RB51 strain pQAE (RB51-QAE), will promote transient colonization of the host 
and elicit an immune response greater than the parental RB51 without producing any 
signs of adverse pathology of in the goat model.  The modified strain of B. abortus 
RB51-QAE was analyzed using an in vivo colonization study in the goat model and in 
vitro experiments focused on hemagglutination, immunogenicity, and protein 
characterization.   
 A second hypothesis for this study proposes that conventional PCR methods are 
sufficient for the detection of both B. melitensis and B. abortus colony forming units in 
whole blood, plasma, serum, and urine.    This hypothesis was tested using uninfected 
whole blood, plasma, serum, and urine to create and test serial dilutions of B. melitensis 
16M and B. abortus 2308 using the Omp25 and Baily primer sets, designed for the 




















COMPARISON OF BRUCELLA ABORTUS RB51 AND RB51 




 Vaccination against brucellosis is an integral tool in efforts to control the disease 
worldwide.  The current vaccine used to protect cattle against bovine brucellosis is B. 
abortus RB51, which lacks the OPS and does not interfere with serological testing 
(USDA 1996). As a rough vaccine, RB51 does not produce a very strong antibody 
reaction in the vaccinated animal; but it does induce a cell-mediated response for 
protective immunity.   RB51 provides limited protection in goats and little to no 
protection in other animals, such as elk and bison, which serve as major U.S. reservoirs 
for B. abortus in the wild (Moriyon et al. 2004).  The Rev.1 vaccine has proven more 
effective in the caprine host, but promotes antibody formation that interferes with 
diagnostic testing.  Development of an improved vaccine that is safe, effective, and does 
not impede standard diagnostic testing could serve as an important advancement in 
eradicating the disease globally. 
 Plasmid QAE (pQAE) was created to study a putative hemagglutinin found in B. 
melitensis.  The QAE plasmid consists of the pBBR1MCS-4 plasmid (which contains an 
ampicillin resistance marker) and a region (designated region E, GI:17989062) from the 
genome of B. melitensis that is hypothesized to contribute to virulence or host specificity.  
The development of pQAE was accomplished by comparing the genomes of B. abortus 
2308 and B. melitensis and finding gene regions that differed.  Once a unique region was 
found in the genome of B. melitensis, this region was investigated, isolated, and cloned 
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into pBBR1MCS, and then electroporated into B. abortus 2308 (Perry 2007).  This new 
strain of 2308 (2308-QAE) was then used to infect pregnant goats.  The results of this 
experiment yielded approximately the same results seen for goats infected with B. 
melitensis, indicating that the region of the B. melitensis genome that was carried by 
pQAE and transferred to 2308 was effective in increasing host specificity (Perry 2007).   
 In addition, the effects of pQAE expression by B. abortus RB51 in the caprine 
host were examined.  Animals were conjunctivally inoculated with either RB51 or RB51 
expressing pQAE (RB51-QAE) and tissue colonization levels were monitored over a 
period of 42 days post-inoculation.  It was expected that RB51-QAE would remain 
attenuated, but survive longer in the tissues, potentially producing a greater immune 
response and thus, a more broadly efficacious vaccine. 
 Successful trials with RB51-QAE may ultimately lead to the development of a 
new, more effective vaccine that will serve as a better tool in the eradication of 
brucellosis than the currently used RB51 vaccine.  Due to the worldwide problem with 
this pathogen and the need for an alternative vaccine, a caprine brucellosis model system 
was developed for testing promising vaccine candidates (Elzer 2002).  Using this 
protocol, a vaccine candidate that incorporates pQAE into RB51 was tested.  The goal of 
this study was to compare the modified RB51 strain (RB51-QAE) with the parental strain 
for colonization levels and pathological effects. 
Materials and Methods 
 
Creation of B. abortus RB51-QAE 
  A 100 μl dose of the B. abortus RB51 (Colorado Serum) parental strain was 
plated on a brucella selective, blood agar (BS-BA) plate and incubated at 37°C in a 5% 
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CO2 atmosphere for approximately 72 hours.  All resultant colonies were harvested and 
used to inoculate 25  ml of sterile Brucella broth.  The cells were incubated overnight in a 
shaking water bath set at 37°C.   
 The culture was then equally divided by placing 1 ml of the total culture into each 
of twenty-five 1.5 ml microcentrifuge tubes.  These cells were pelleted, the supernatant 
discarded, and the pellets were combined into a single microcentrifuge tube.  The pellet 
was washed a total of 5 times in sterile dH2O then re-suspended in 100 μl of cold, sterile 
dH2O. 
 For electroporation, 33 µl of the suspended RB51 cells were combined with 3 µl 
of cold pQAE plasmid solution in an Eppendorf Electroporation Cuvette.  The cuvette 
was then placed in an Eppendorf 2510 Electroporator set at 2.5kV and was electroporated 
for 5.6 ms.  Immediately after electroporation, the cells were supplemented with 500 µl 
of cold, sterile SOC-B recovery media.  The cells were then left overnight in a shaking 
water bath set at 37°C. 
 The next morning, BA plates containing 100 µg/ ml ampicillin were used to 
spread 100 µl of the electroporated RB51-QAE cells.  These plates were incubated for a 
period of 2 weeks in a 37ºC, 5% CO2 environment and observed for growth daily after 
the initial 72 hours.   
All of the colonies growing after this 2 week period were suspected to be RB51-
QAE colonies and were tested accordingly.  All resultant colonies tested positive for 
oxidase, catalase, and urease tests, which is typical for B. abortus colonies.  Furthermore, 
a miniprep plasmid isolation was performed on rando mly selected colonies and the 
pBBR1MCS-QAE plasmid was identified from these colonies.  To detect the presence of 
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region E in the isolated pQAE DNA, the cells were chloroform killed and a restriction 
enzyme digestion using EcoR V (New England Biolabs) and PCR was performed, both 
targeting the region E portion of pQAE.  Samples of the pure pQAE plasmid, as well as 
samples obtained through miniprep procedures following tissue culture, were sequenced 
using BioMMED (Baton Rouge) facilities. 
Confirmation of pQAE in B. abortus RB51-QAE 
Plasmid isolation was performed using the Qiagen Buffer System kit (Qiagen, 
Inc.) to verify the presence of pQAE in RB51-QAE cells.  A broth culture of RB51-QAE 
was allowed to incubate at 36°C overnight in a shaking water bath.  Two ml of the 
culture was pelleted by centrifuge at 9000rpm for 5 minutes and the supernatant was 
separated then discarded.  The pellet was then re-suspended in a series of three buffers; 
300μl of Bufer P1 (50mM Tris base; 10mM EDTA, pH 8; 100 μg/ ml RNase A), then 
300 μl of Buffer P2 (200mMNaOH, 1% SDS), and lastly 300 μl of chilled Buffer P3 (3.0 
M CH3CO2K, pH 5.5).  The tubes were vortexed after the addition of Buffer P1 and 
mixed by inverting the tubes after the addition of Buffers P2 and P3.  The tubes were 
centrifuged at 14,000 rpm for 10 minutes, after which the supernatant was transferred to a 
clean 1.5  ml microcentrifuge tube.  The volume of the supernatant was measured and an 
amount of isopropanol 0.7 times that of the total volume was added.  The tubes were 
inverted multiple times to precipitate the DNA and centrifuged for 15 minutes at 14,000 
rpm.  The supernatant was discarded, the DNA pellet was allowed to air dry, and was 
then re-suspended in 25 μl of sterile dH2O.  
Following plasmid DNA isolation, a Polymerase Chain Reaction (PCR) 
amplification targeting the region E gene sequence was performed.  The FailsafeTM PCR 
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System was used for this procedure, specifically with 2X Premix G (Epicentre 
Biotechnologies).  Twelve 2X Premixes (A-L), each containing a specific mix of dNTPs, 
buffer, and varying amounts of MgCl2 and FailSafe™ PCR Enhancer (with betaine), were 
subjected to a PCR assay with a control sample of region E DNA.   
 Reactions of 30μl were prepared for each of the pQAE isolation samples.  For 
each sample, 0.75 units of Failsafe PCR Enzyme Mix, containing a mix of thermostable 
DNA polymerases, were added with 2X Premix G, 0.2μM of each primer, sterile dH2O, 
and approximately 300 ng of template DNA.  The primers used for this assay, ORF-944F 
(5’-GAATTGGCGACCTGACTGAGGA- 3’) and ORF-944R (5’-
CTCACGGCTGTTCTCCTTTAACA- 3’), were designed to target the 1988 bp gene 
sequence of region E.  These primers were designed through The Institute of Molecular 
Biology and Medicine at the University of Scranton (Scranton, PA) using the B. 
melitensis 16M choromosome II gene sequence (Genbank Accession Number 
AE008918).  The primers were produced by Integrated DNA Technologies, Inc. 
(Coralville, IA), re-suspended upon arrival using sterile dH2O, and stored at -20°C. 
 The PCR samples were placed in a MyCyclerTM Personal Thermal Cycler (BioRad 
Laboratories, Inc., Hercules, CA).  For the optimal amplification of Region E, an initial 
denaturation step of 96°C was held for 5 minutes.  Each reaction was then subjected to 
denaturation at 96°C for 1 minute, annealing at 55°C for 30 seconds, and extension at 
72°C for 2 minutes over 30 cycles.  Lastly, a prolonged extension phase was programmed 
for 5 minutes at 72°C.  The amplified samples were stored at 4°C until visualization with 
agarose gel electrophoresis using ethidium bromide staining.   
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A restriction enzyme digestion was performed using EcoRV (New England 
Biolabs) on the pQAE miniprep isolations purified from RB51-QAE. The purpose of this 
procedure was to excise the region E gene sequence (approximately 2kb) from the pQAE 
plasmid (approximately 4kb) for visual confirmation using agarose gel electrophoresis.  
Twenty units of EcoRV were used with 2.5μl 100μg/ ml bovine serum albumin (BSA), 
2.5μl of 1X NEBuffer3, and a volume of dH2O to bring the total volume to 25μl.  The 
reactions were incubated for 1 hour at 37°C in a shaking water bath under slight 
agitation.  To deactivate the restriction enzyme activity, the samples were placed in a 
85°C heating block for 20 minutes.   
Agarose gel electrophoresis was used to visualize the DNA products of PCR, 
restriction enzyme digestion, and plasmid and genomic DNA isolation.  A 5μl sample of 
each DNA preparation was mixed with 5μl of 6X loading buffer (12% Ficoll 4000, 1.0 M 
Na2EDTA, pH 8, 0.6% SDS. 0.15% bromphenol blue) and loaded onto a 1% agarose gel.  
Molecular weight standards of either 100bp, 1 kb, or a supercoiled molecular weight 
ladder (New England Biolabs) were run on each gel to determine the approximate size 
and concentration of each DNA sample.  The gel was made using UltraPureTM Agarose 
(Invitrogen Corporation) in TAE buffer (Tris-base, Na2EDTA, glacial acetic acid).  Each 
gel was run in a BioRad DNA Sub Cell (BioRad Laboratories, Inc.) at 100V until the dye 
front reached a distance of approximately 1 inch from the end of the gel.  The gel was 
stained in 1.0 μg/ ml ethidium bromide for 5-10 minutes, and then destained for 30 
minutes to 1 hour in dH2O.  The gels were next placed on a UV Transilluminator for 
visualization.  Documentation was performed using the PhotoDoc-It Imaging System 
(UVP, LLC) to photograph each gel. 
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Making of Infectious Doses 
RB51-QAE colonies from the electroporation experiment that were proven to 
contain pQAE were spread on three BA-AMP plates and incubated at 37ºC in a 5% CO2 
atmosphere for approximately 72 hours.  The cells were harvested from each plate using 
2 ml of sterile broth per plate and the cells from all plates were combined in a single tube.  
A tube containing 12 ml sterile broth was then inoculated with 50 µl of the harvested 
cells and the optical density (OD) was determined (at 600nm).  The desired absorbance 
reading of 0.150 was obtained and is indicative of a 1x109 dilution.  Using this 
information, two tubes were prepared; the first with 6 ml broth and 2.5  ml culture for a 
dilution of 1x1011, and the second with 24 ml broth and 100 µl culture for a dilution of 
1x109.  These dilutions were divided into 1 ml portions and placed in individual  tubes, 
which would serve as the infectious doses for this experiment.  The tubes were flash 
frozen and placed in a -80ºC freezer until needed.  Plate counts were performed to ensure 
the approximate cell count for one tube from each of the dilution groups.   The results of 
these plate counts confirmed an accurate CFU/ ml for each of the dilutions tested. 
Animals 
 Twenty Brucella negative goats were divided into 2 groups of 10.  Group 1 was 
inoculated conjunctivally with commercially available RB51 vaccine (1x1010 colony 
forming units), group 2 with the RB51-QAE vaccine (1x1010 colony forming units).  
Blood samples were collected from each animal prior to inoculation and on the day of 
necropsy.  Initial blood samples were collected using Precision Glide Vacutainer Blood 
Collection Needles (Becton Dickinson and Co.) in association with 10 ml BD red-top 
Vacutainer Serum tubes (Becton Dickinson and Co.).  The blood samples were allowed 
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to clot overnight then centrifuged for separation.  The serum was drawn off, subjected to 
a Brucellosis card test, then stored for later use at -20°C.  Blood collected at necropsy 
was obtained through exsanguination.   
 From each of the groups, two goats were euthanized at 7, 14, 21, 28, and 42 days 
post-vaccination using captive-bolt and exsanguination methods.  Tissue samples 
obtained at necropsy included the parotid lymph node, prescapular lymph node, liver 
portions, spleen portions, internal iliac lymph node, and the supramammary and inguinal 
lymph nodes of female and male goats, respectively. The individual tissues were 
homogenized in 20 ml PBS, and 100μl were spread onto Brucella selective media (Oxoid 
Ltd., Basingstoke, Hampshire, England) (Farrell 1974) then allowed incubate at 37°C for 
a period of 2 weeks.   
Bacteriological Examination 
Resultant colonies were confirmed as Brucella or non-Brucella by the 
morphological appearance of each colony and the activity of the colonies in question 
when submitted to oxidase, catalase, and urease tests. Suspect RB51-QAE colonies were 
also subjected to plasmid isolation and PCR targeting region E to ensure the presence of 
region E in these cells.  The confirmed Brucella colonies were counted and recorded in 
the form of a growth chart comparing the time of sacrifice post-immunization and the log 
CFU per organ for each of the vaccines tested.  
A series of 10 biochemical tests were also performed to compare the results of B. 
abortus 2308, RB51, and RB51-QAE.  B. abortus 2308 was included because it is the 
smooth parental strain of RB51.  These tests included a Gram stain, serum agglutination, 
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an acriflavin test, oxidase, catalase, urease, H2S, and TSI tests as well as dye sensitivity 
tests with Thionin and Basic Fuchsin.  
Serum agglutination was performed to determine a rough or smooth phenotype of 
RB51 and RB51-QAE.  This test was performed by placing a drop of commercially 
available antisera against Brucella OPS (Fisher Scientifics) onto a clean glass slide and 
mixing with it a suspect colony of RB51 from a Brucella Selective blood agar plate.  The 
same procedure was performed for suspect colonies of RB51-QAE.  The results were 
read based on the occurrence or absence of agglutination observed on the slide.  Smooth 
brucellae will cause agglutination, whereas rough brucellae will not.   
 Gram negative organisms with a rough phenotype will agglutinate when mixed 
with acriflavin.  This test was used as another method of determining the rough or smooth 
characteristics of RB51 and RB51-QAE.  For this test, a fresh solution of 10mg acriflavin 
in 10 ml of sterile dH2O was made.  A small volume of this solution was placed onto a 
clean glass slide, then mixed into suspension with a colony of either RB51 or RB51-QAE 
from an agar plate.  The suspensions were observed for agglutination and the results 
documented. 
RB51 and RB51-QAE were also tested for the ability to produce cytochrome 
oxidase, which reduces molecular oxygen, using the oxidase test.  An oxidase reagent 
ampule (Becton Dickenson and Co., Cockeysville, MD) was prepared by breaking the 
ampule and mixing the contents within.  Using a sterile cotton swab, a colony of either 
RB51 or RB51-QAE was selected from an agar plate.  The oxidase reagent was dropped 
onto each swab and observed for 30 seconds.  The results were read by the absence or 
appearance of a violet color on the swab within 30 seconds. 
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Catalase is an enzyme capable of converting hydrogen peroxide into oxygen and 
H2O.  To test for the presence of this enzyme in RB51 and RB51-QAE, a loop of each 
organism was chosen from an agar plate and smeared onto a clean glass slide.  One to 
two drops of a commercial catalase reagent (Becton Dickenson and Co.) was added to 
each slide and mixed with the suspect colonies of each strain.  The test was read by the 
formation or absence of oxygen bubbles forming within the mixture. 
 To test for the ability of RB51 and RB51-QAE to produce urease, which breaks 
down urea into ammonia, CO2 and H2O, a urease test was performed.  Urease slants 
(Remel, Inc.) containing a pH indicator were streaked with an isolated colony of either 
RB51 or RB51-QAE.  The urease slants were incubated at 37°C in a 5% CO2 atmosphere 
for 24 hours.  The results were read by the presence or absence of a pink color produced 
by the pH indicator, which will change colors in a basic environment. 
 A Hydrogen Sulfide (H2S) test was performed to test the ability of each strain 
tested to produce H2S from amino acids containing sulfur.  Triple sugar iron (TSI) media 
(Remel, Inc.) was inoculated with either RB51 or RB51-QAE.  A commercially available 
lead acetate strip (Sigma-Fluka, Inc.) was secured between the cap and inner wall of the 
media tube.  The tubes were incubated overnight at a temperature of 37°C in a 5% CO2 
atmosphere.  The results were read by observing the development or absence of a black 
color on the lead acetate strip.  Using the same TSI media inoculated with either RB51 or 
RB51-QAE, a TSI test was performed.  The results were read at the same time as the H2S 
test by observing the media for changes in color and the production of gas bubbles. 
Dye sensitivity tests were performed for each strain using Thionin and Basic 
Fuchsin.  Plates were made using agar containing either Thionin or Basic Fuchsin (Hardy 
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Diagnostics) then streaked with suspected colonies from RB51 or RB51-QAE that had 
been suspended in a sterile saline solution.  A positive control plate was also prepared.  
Each plate was incubated at 37°C in a 5% CO2 atmosphere for a period of 3-4 days to 
allow for adequate growth.  The results were determined by the presence or absence of 
growth in the presence of Thionin and Basic Fuchsin.   
Serological Examination 
 A blood sample from each of the test animals was taken prior to infection and at 
the time of sacrifice.  These samples were spun down and the serum extracted.  The 
Brucellosis Card Test (Obtained from USDA, APHIS, manufactured by Becton 
Dickenson and Co.) was performed for each of the pre-bleed samples as well as for each 
of the post-inoculation samples.  A 30μl volume of Buffered Brucella Antigen (BBA) 
(Becton Dickinson and Co.) was placed onto a Brewer Diagnostic Card (Becton 
Dickinson and Co.) with a 30μl sample of serum from each goat.  A sterile toothpick was 
used to mix each serum sample with the BBA until a uniform suspension was achieved.  
The samples were then rocked for a period of 4 minutes and observed for agglutination. 
 The serum from each goat was also used to perform western blots on all pre-bleed 
and post-inoculation samples for the purpose of monitoring the antibody immune 
response for each animal.  The blots included lysates of both RB51 and RB51-E, as well 
as several other strains of Brucella, both rough and smooth. 
 Cell lysates of B. abortus 2308, B. abortus RB51, B. abortus RB51-QAE, B. 
melitensis 16M, B. suis VTRS-1, Y. enterocolitica 0:9. and Y. enterocolitica 0:8 were 
prepared for western immunoblots through the method of sonication.  For sonication, 
each species of bacteria were grown on selective media plates.  Each culture was 
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incubated for 2-3 days at 37°C in a 5% CO2 atmosphere.  The bacteria were harvested 
using 2 ml of sterile PBS (Sigma Chemical Company) for each plate.  Each volume of 2 
ml was sonicated using a Heat Systems-Ultrasonics W-385 Sonicator (Farmingdale, NY) 
for 8 minutes with a 50% duty at a 1-second pulse and a 4.0 to 4.5 output.  A loop of the 
resultant lysates were spread onto one half of a selective media plate and the rest boiled 
for 10 minutes.  A loop of the sonicated and boiled lysates were spread on the second half 
of the selective media plate and allowed to incubate for 2-3 days to confirm that the 
Brucella cell lysates are no longer viable.  To prepare the lysates for western 
immunoblotting, a 150μl volume of lysate was mixed with a 150μl volume of Laem mli 
Sample Buffer (BioRad Laboratories) prepared with a 0.1 volume of 2-mercaptoethanol 
and boiled for an additional 10 minutes.   
 Coomassie staining was used to determine the ideal volume of each lysate to be 
used in polyacrylimide gel electrophoresis (SDS-PAGE).  Based on these results, 
volumes between 3 and 5μl of each lysate was loaded onto a precast 12% Tris-HCl Ready 
Gel (BioRad Laboratories) with a Kaleidescope Prestained Standard (BioRad 
Laboratories) size standard marker.  The gels were run in a Criterion Precast Gel System 
(BioRad Laboratories) at 150V for a period of 1 hour and 15 minutes to 1.5 hours until 
the dye front reached the bottom of the gel.   
 Proteins were transferred to a nitrocellulose membrane (Osmotics, Livermore, 
CA) at 100V for 1 hour at 4°C.  The membrane was blocked in a 5% solution of Blotting 
Grade Blocker Nonfat Milk (BioRad Laboratories) in Tris-Buffered Saline (0.5M NaCl, 
20mM Tris) (TBS), incubated for 1 hour on a rocker at room temperature, washed with 
TBS-Tween (TBS, Tween-20) 5 times and once with TBS.  Each individual blot was 
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incubated overnight in a 1:40 dilution of test serum on a shaker at room temperature, and  
washed again as before.  The immunoblots were immersed a 1:800 dilution of rabbit anti-
goat IgG horseradish peroxidase (Sigma-Aldrich Co., St. Louis, MO) on a shaker in room 
temperature for 45 minutes.  Blots were developed in a TBS-methanol-3% hydrogen 
peroxide solution using 4-chloro-1 napthol tablets (Sigma-Aldrich Co.) for visualization, 
stopped in dH2O, and air dried.  
Histopathological Analysis 
 Histopathology was performed by Dr. Eric Snook at the School of Veterinary 
Medicine, Louisiana State University.  Tissue samples from necropsy were fixed in 10% 
neutral buffered formalin and embedded in paraffin.  Each slide was stained using 
hematoxylin and eosin then examined for pathology.   
Results 
Creation of B. abortus RB51-QAE 
  The resultant colonies that grew on the BA-Amp plates following electroporation 
were subjected to further testing in order to ensure that the surviving colonies were 
Brucella spp. and carried the pQAE DNA with the region E gene (Figure 1  A & B).  All 
colonies tested catalase, oxidase, and urease positive, confirming the colonies as Brucella 
spp.  A plasmid isolation miniprep was performed on the suspect RB51-QAE colonies 
and further tests such as PCR and restriction enzyme digestion, both targeting region E of 
the plasmid DNA, were used for confirmation.   Sequencing information obtained for 
pQAE was analyzed and confirmed the presence of the region E gene sequence in pQAE.   
 The resultant plasmid DNA from the miniprep procedure was run on an agarose 
gel with a size standard and a positive and negative control, stained with ethidium  
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(A) Region E gene sequence with ORF-944F and ORF-944R primer sequences in red. 
 
(B) Diagram of the pBBR1MCS-4 





bromide, and analyzed under UV light.  A band of approximately 4950 bp in length was 
observed for all of the plasmid DNA tested, suggesting that the colonies in question 
carried the 4950 bp pQAE (data not shown).   
 A PCR experiment was set up and run with primers (Orf944F and Orf944R) 
targeting the region E portion of pQAE miniprep isolated from the suspect RB51-QAE 
colonies.  The resultant amplified DNA was run on a 1% agarose gel with a supercoiled 
DNA molecular weight ladder and controls, stained, and analyzed under UV light.  A 
band of approximately 2000 bp was observed in each of the test sample lanes, confirming 
the presence of region E in the plasmid DNA isolated from the suspect RB51-QAE 
colonies (Figure 2).   
 For further confirmation, a restriction enzyme digest using EcoRV, targeting 
region E, was also performed on the plasmid DNA from the colonies in question.  The 
digests were run on a gel with a size standard, controls, and the intact plasmid DNA of 
each digested sample.  The resultant gel produced bands of approximately 4950 bp in 
length corresponding to the intact DNA, and bands of approximately 2000bp in length 
corresponding to the lanes of digested DNA (data not shown).  Therefore, the results of 
this digest further confirmed the presence of region E in the plasmid DNA isolated from 
the suspect RB51-QAE colonies. 
 Due to the results of the plasmid isolation and subsequent sequencing, PCR, and 
restriction enzyme digest performed on the RB51-QAE colonies in question, it is 
confirmed that the electroporation procedure was successful and that the resultant RB51-










Agarose gel electrophoresis of plasmid minipreps performed on 3 suspected RB51-QAE 
colonies amplified by PCR using the ORF-944F and ORF-944R primers and run by 
agarose gel electrophoresis.  The bands are approximately 2000bp in size, according to 
the standard molecular weight marker shown.   
 
The lane order is as follows: 
 Lane 1 – 1kb Molecular Weight Ladder 
 Lane 2 – Negative control group of dH2O 
 Lane 3 – PCR products from B. abortus RB51 
 Lane 4 - PCR products from miniprep DNA isolated from RB51-QAE suspect 1 
 Lane 5 - PCR products from miniprep DNA isolated from RB51-QAE suspect 2 
 Lane 6 - PCR products from miniprep DNA isolated from RB51-QAE suspect 3 


















In order to better characterize RB51-E, 10 general biochemical tests, including 
dye sensitivities were performed for RB51-QAE, the standard RB51 vaccine strain, and 
B. abortus 2308.  The results of these tests for RB51 and 2308 matched the typical results 
seen for RB51 and 2308.  The results produced by RB51-QAE were identical to those 
seen for the standard RB51 vaccine strain (Table 1).  
To evaluate the colonization capabilities of RB51-QAE in the caprine host, 
twenty non-pregnant goats were conjunctivally inoculated with 1×1010 colony forming 
units (CFU) of either RB51-QAE or RB51.  Following the necropsy of each animal at 7, 
14, 21, 28, and 42 days post inoculation, each of the 6 tissues collected per animal were  
homogenized and a portion of each tissue was plated onto a BS-BA plate as well  
as a BA-Amp plate.  The resultant colonies from each animal at each time of sacrifice 
were counted and recorded.  The overall culture results showed that the tissues from 
animals inoculated with RB51-QAE yielded a significantly higher bacterial titer at 14, 21, 
and 28 days post-inoculation than the tissues from animals inoculated with RB51.  RB51- 
QAE was also shown to survive longer in the host tissues than standard RB51 (Figure 3) 
(Table 2).  It should be noted that the results obtained for 14 days post-inoculation for the 
RB51 group are not typical when compared to previous studies examining the survival of 
RB51 in the caprine host.  In most instances, RB51 is capable of surviving up to 21 days 
post-inoculation.  The absence of RB51 in the 14 day post-inoculation group could be 
due to errors in vaccine administration or deficiencies within the animals tested.   
Only one confirmed Brucella colony was detected for either group at 42 days post 





Results of ten biochemical tests performed on 2308, RB51, and RB51-QAE.  The results 
for 2308 and RB51 were expected and consistent with previous findings.  RB51-QAE 
produced results similar to RB51, indicating that the addition of the pQAE plasmid did 











2308 Smooth neg + – + + + + – – + 
RB51 Rough neg – + + + + + – – + 



























Figure 3.  Colonization of male and non-pregnant female goats with RB51 and RB51-
QAE in average CFU/gm of tissue from parotid and prescapular lymph nodes taken at 7, 




























Table 2.  Colonization of goats with B. abortus RB51 and B. abortus RB51-QAE in 






Test Par LN CFU/g PreS LN CFU/g Liv/Spl CFU/g 
          
7 DPI O-26 RB51 negative 37 3.72E+03
No 
Growth – 2 4.22E+01
 26 RB51 negative 4 8.19E+02
No 
Growth – 1 2.36E+01
 O-20 
RB51-
QAE negative 40 4.58E+03
No 
Brucella – 1 2.00E+01
 Y-32 
RB51-
QAE negative 62 2.46E+03
No 
Growth – 1 1.98E+01
          





















QAE negative 4 7.05E+02
No 
Growth – 1 2.20E+01
          














QAE negative 315 2.36E+04 1 5.03E+01 1 1.97E+01
 Y-23 
RB51-
QAE negative 200 3.11E+04
No 
Growth – 6 2.31E+01
          























QAE negative 39 6.41E+03 7 5.09E+02 6 2.33E+02
          



































testing by plasmid isolation and PCR analysis, it was found to be an RB51-QAE colony.  
It was assumed that this colony was the result of a contamination during necropsy.   
Serological Examination 
 Each of the animals used for this study were subjected to pre-inoculation and 
post-inoculation serum testing.  A pre-inoculation serum sample and a post-inoculation 
serum sample, taken at the time of sacrifice, were tested for each animal by a standard 
brucellosis card test.  Each of the animals tested negative before and after inoculation for 
Brucella-specific smooth antibodies. The pre and post inoculation samples were used to 
run a set of western blots for each animal.  The western blots contained the lysates of B. 
melitensis 16M, B. suis VTRS-1, B. abortus 2308, RB51, RB51-QAE, B. ovis, and B. 
canis.  The results of RB51-QAE inoculated goats on the western immunoblot assay 
yielded an equal or greater humoral immune response in the goats tested as compared to 
blots run for RB51 goats during the same time points (Figure 4).   
Histopathology 
 There appeared to be no definitive histological pattern in the liver and spleen with 
respect to the time or type of infection in any animal.  At day 28, the RB51 group 
subjectively appeared to have an increased follicular activity as compared to RB51-QAE 
in some lymph nodes.  At day 42 the RB51-QAE group had a subjectively increased 
follicular activity over RB51 (data not shown).  
Discussion 
 In 2007, Perry hypothesized that addition of the Region E sequence via the pQAE 
plasmid to B. abortus 2308 would increase virulence in the caprine model and that the 
absence of Region E from B. melitensis 16M would cause attenuation in the caprine 
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21 days post-inoculation 28 days post-inoculation 







Characteristic western immunoblots showing an increase in humoral response in goats 
inoculated with RB51-QAE. These results are from representative goats sacrificed at 21, 
28, and 42 days post-inoculation.  The first blot in each group shows the results of a pre-
inoculation sample and the second shows the results of the post-inoculation sample taken 
during necropsy on the days specified. 
  
The order of lysates, as follows, is numbered on the first blot of this figure and the same 
order remains throughout: 
 
 1.  B. melitensis 16M  5.  B. abortus RB51 
 2.  B. abortus 2308  6.  B. canis 
 3.  B. suis VTRS-1  7.   B. ovis 








model described by Elzer et al. in 2002.  It was demonstrated that the addition of Region 
E to B. abortus 2308 resulted in a significant increase in colonization and pathogenicity 
in goats, when conjunctivally inoculated.  The B. melitensis 16M Region E deletion 
mutant (16MΔE) did not cause decreased colonization when compared to the parent 
strain, but did result in a decrease in pathogenesis in the caprine host (Perry 2007).  
Further investigation of the Region E protein as a putative hemagglutinin and host 
specificity factor was merited.   
 This study uses the caprine model to test the effects of the Region E gene addition 
to B. abortus RB51 (RB51-QAE) .  Furthermore, the characterization of the Region E 
protein as a putative hemagglutinin, cell surface protein, host specificity factor, and 
immunogenic determinant was explored.  It was hypothesized that addition of the Region 
E protein, via pQAE, would increase virulence of RB51 in the caprine model described 
by Elzer et al. in 2002.  It was also proposed that the Region E protein was a cell-surface 
hemagglutinin and host specificity factor capable of inducing anti-Region E protein 
antibodies in the caprine host.  Both the parental strain of RB51 and the RB51 region E 
variant (RB51-QAE) were examined in the caprine host for effects on colonization using 
both male and non-pregnant female goats.  The hemagglutinating abilities of the region E 
protein were evaluated using RB51 and RB51-QAE in a hemagglutination assay 
examining cell harvest, broth culture, and supernatant samples using both goat and cow 
erythrocytes.  Absorption assays were also performed using serum from goats infected 
with comparison strains of Brucella with and without the presence of the Region E gene 
sequence (specifically, 16M and 16MΔE, 2308 and 2308-QAE, RB51 and RB51-QAE). 
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 The RB51-QAE mutant was examined using ten biochemical tests (described 
previously) and it was demonstrated that the addition of pQAE did not make the 
organism biochemically different from the parental strain.  When subjected to a Rose 
Bengal card test, serum from neither experimental group provided positive test results.  
This indicates that the addition of pQAE to B. abortus RB51 did not result in converting 
the strain from rough to smooth.  Furthermore, a noticeable increase in humoral detection 
by western immunoblots was observed when compared to the parental RB51 strain, 
suggesting that RB51-QAE has an increased immunogenicity when compared to the 
parental strain.   
 The addition of pQAE provided RB51-QAE with specific attributes that may have 
enabled the organism to increase its colonization in a caprine host.  At day 7 post-
inoculation, both RB51 and RB51-QAE successfully colonized the parotid lymph nodes 
and were detected in the liver and spleen.  This outcome was typical of an RB51 
colonization in the caprine model. At day 14 post-inoculation, only RB51-QAE was 
cultured from necropsy.  None of the RB51-inoculated animals produced Brucella 
colonies from any of the tissue samples tested.  This may be due to an error in sample 
collection, sample preparation, or bacteriologic technique.  Additionally, this result may 
also be attributed to inoculation errors or physiological issues involving the animal itself.  
Typically, RB51 is able to colonize tissues of the caprine host for approximately 21 days 
post-inoculation, which further supports our day 14 post-inoculation results as erroneous 
(Adone et al. 2005, Neilson et al. 2004).  As shown by the day 21 post-inoculation 
animals, RB51 continued to colonize the parotid lymph nodes in the animals tested, 
indicating the erroneous nature of the day 14 post-inoculation findings.  In this same 
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group, the RB51-QAE goats sacrificed at 21 days post-inoculation were identified in the 
parotid lymph nodes, the prescapular lymph node, and in liver and spleen tissues.  In 
addition, only RB51-QAE was cultured from the day 28 post-inoculation animals, 
supporting the proposal that RB51-QAE is able to survive for a longer period in the 
caprine model than the parental strain.  On day 42 post-inoculation, no significant culture 
growth was detected from any of the animals or tissues tested.  A single colony was 
detected and confirmed as RB51-QAE, but this result is not significant.   
 The results of the tissue culture assays show that RB51-QAE is able to colonize 
the host more effectively than the parental strain RB51.  The results of this experiment as 
a whole merit further investigation into the function of RB51-QAE as a vaccine 
candidate.  Future studies to determine the pathogenicity and, subsequently, vaccine 
efficacy in goats and other primary host and reservoir animals are currently in planning.  
Because smooth vaccines interfere with diagnostic tests and are an obstacle to eradication 
efforts, a rough vaccine applicable in goats and would be a useful tool in reducing the 




















CHARACTERIZATION OF A PUTATIVE 
HEMAGGLUTININ OF BRUCELLA MELITENSIS 
EXPRESSED BY THE REGION E GENE 
 
Introduction 
   
 Determining the functional characteristics of the protein expressed by the region 
E gene is important in evaluating its role in the increased colonization capabilities of 
RB51-QAE in the caprine host.  Strains of B. abortus lack the region E gene and are not 
as effective in colonizing goats as strains of B. melitensis, which naturally express the 
region E gene.  The region E protein was shown to increase colonization of both B. 
abortus 2308-QAE and RB51-QAE in goats, suggesting that the addition of region E may 
confer host-specificity to strains of B. abortus in the caprine host.  The protein expressed 
by region E is referred to as a putative hemagglutinin and cell wall surface protein when 
examined through a BLAST search. 
 In evaluating the potential of RB51-QAE as an improved vaccine candidate, it is 
important to determine if the protein is expressed by RB51-QAE and, if expressed, the 
functional aspects of the region E protein in the caprine host.  Two-dimensional gels were 
created and mass spectrometric analysis was used to determine expression of the region E 
protein in RB51-QAE and a strain of E. coli DH5α that has been made to express the 
region E gene (DH5α-TOPOE), but the protein was not detected in the gels.  
Hemagglutination assays were prepared with bacterial strains expressing pQAE to 
evaluate the hemagglutinating capabilities of region E protein.  The immunogenic 
characteristics of region E were assessed using western blot absorption analysis using 
serum from goats inoculated with strains of Brucella expressing the region E gene. 
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Materials and Methods 
 
Preliminary Characterization 
 The region E gene was analyzed using the NCBI Basic Local Alignment Search 
Tool (BLAST) and the B. melitensis genome surrounding region E was examined using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) online database. 
Bacterial Preparations for Hemagglutination Assay 
 The strains of bacteria studied in the hemagglutination assay were chosen based 
on the presence or absence of the region E protein in the genome and tested against 
mutant strains that either contained a plasmid expressing the region E gene, or a deletion 
mutant that is devoid of the region E gene sequence.  The bacterial strains used are as 
follows:  B. abortus RB51 & B. abortus RB51-QAE and E. coli DH5α & E. coli DH5α-
TOPOE.  Previously stored cell lysates for all of the strains tested were subjected to 
hemagglutination assays using goat erythrocytes.  Both strains of E. coli DH5α were 
grown previously and stored in glycerol stocks at -80°C.  DH5α-TOPOE expresses the 
TOPOE plasmid, which is a high-expression vector that contains a copy of the region E 
gene as well as a kanamycin resistance gene for selection.  To confirm the presence of the 
region E gene in the TOPOE plasmid, the plasmid was sequenced using BioMMED 
(Baton Rouge).  Both B.abortus RB51 and RB51-QAE lawns were grown as previously 
described on selective SBA plates, with RB51-QAE being grown on plates containing 
ampicillin at a concentration of 1μl/ ml media.  Two series of SBA plates were prepared 
with one set containing bovine blood and the second containing caprine blood.  Both 
RB51 and RB51-QAE were grown on both sets of blood SBA plates and harvested in 2 
ml of sterile PBS (Sigma Chemical).  Both E. coli DH5α and E. coli DH5α-TOPOE were 
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grown on LB agar media and similarly harvested.  The LB agar plates used to grow 
DH5α-TOPOE were prepared with a 1μl/ ml media concentration of kanamycin for 
selective purposes.  All cell suspensions were analyzed by spectrophotometer at an 
OD600nm reading of 0.75 to equalize cellular concentrations of each experimental group.  
Each sample was then subjected to hemagglutination assays. 
 Broth cultures were also prepared for each of the RB51 and DH5α strains in 2 ml 
of broth in a 15 ml centrifuge tube.  B. abortus bacteria were grown in brucella broth 
(Becton Dickinson and Co.).  Ampicillin was added to the broth culture containing 
RB51-QAE at a concentration of 100 μg/ ml of broth.  Control tubes were also set up 
with one control brucella broth culture containing no specimen and a brucella broth 
culture containing ampicillin inoculated with RB51.  Broth cultures for E. coli were 
prepared in LB broth.  Kanamycin was added to the broth culture containing DH5α-
TOPOE.  A control tube was prepared with LB broth and no added inoculate.  A second 
control was also prepared using LB broth containing kanamycin at a concentration of 
45μg/ ml of broth and inoculated with DH5α.  Each culture was placed in a water bath set 
to 37°C with moderate agitation.  The E. coli cultures were allowed to incubate 
overnight, and the B. abortus cultures were allowed to incubate for a period of 3 days.  
Following incubation, a 500ul portion of culture was separated and centrifuged.  The 
supernatant was separated and subjected to a hemagglutination assay.  The remaining 
broth culture was subjected to a hemagglutination assay as a whole. 
Erythrocyte Preparation 
 Erythrocytes from both bovine and caprine sources were used for the 
hemagglutination assays to assess the host-specificity of the putative hemagglutinin.  A 
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blood sample was collected using a 10 ml BD Vacutainer tube (Becton Dickinson and 
Co.) containing EDTA as an anticoagulant.  The sample was mixed and aliquoted into 
500μl portions in sterile 1.5 ml micro centrifuge tubes.  The contents of each tube were 
centrifuged at 3000rpm for 3 minutes, the plasma was drawn off, the erythrocyes were 
sspended in 500μl of sterile PBS.  This rinsing step was repeated 4 additional times and 
the final erythrocyte suspension was stored for no more than 3 days at 20°C.  Both 
caprine and bovine erythrocytes were prepared and stored in this manner and used to 
make a 2% solution for each of the hemagglutination assays. 
Hemagglutination Assay Technique 
 Hemagglutination assays were prepared in 96 Well “U” Bottom Plates (Corning 
Incorporated, Corning, NY) containing 100μl sterile PBS per well with (Sigma 
Chemical) 200μl of each cell suspension or culture sample in the first well of the series.  
Two fold dilutions were made by adding 100μl of the initial sample into 100μl of PBS in 
the next well and 100μl of either bovine or caprine erythrocytes were added to each well.  
A control of PBS was also included.  The samples were allowed to incubate overnight.   
 A hemagglutination assay using only the supernatant from each broth culture was 
also prepared to assess localization of hemagglutinating factors as either cell associated 
or secreted using similar techniques.  The supernatant samples were not adjusted 
according to OD600nm calculations, as readings were identical, suggesting that a 
comparable amount of supernatant proteins were already present in each sample.   
Visual Analysis 
 Plates were read visually according to the presence of a button or matte in the 
well, the size and color of each button present, and the color and clarity of the PBS 
 71
suspension in each well.  Because the bacterial cells settled to the bottom of the well, 
each plate was read from the bottom.  
Absorption Assay 
 Absorption assays were performed to detect host antibodies to the region E 
protein by way of western immunoblot for the purpose of further characterizing the 
region E protein as it is expressed in vivo.  Samples were obtained from goats previously 
infected with B. abortus 2308-QAE, B. melitensis 16M, and B. abortus RB51-QAE.  The 
serum from goats infected with strains of 2308-QAE and 16M were from a previous 
experiment performed in this lab and the serum sample from the RB51-QAE goat was 
from the colonization experiment previously described.   
 An amount of 1 ml of each serum sample was combined with 1 ml of 2308 (for 
2308-QAE), RB51 (for RB51-QAE) and 16MΔE (for 16M) lysates in a sterile 
microcentrifuge tube.  The tubes were then placed on a rocker for 2 hours to allow 
absorption of Brucella-specific antibodies.  The tubes were removed from the rocker, 
centrifuged at full speed for 5 minutes to pellet cells, then the remaining serum was 
drawn off for western blot analysis.  
 The western blot analysis to detect antibody to the region E protein was 
performed as previously described and the lane order was as follows:  a size standard 
marker, RB51, RB51-QAE, 2308, 2308-QAE, 16MΔE, and 16M.  The western blots 
were analyzed visually following development. 
Membrane Isolation 
 Two dimensional gels were run for both B. abortus RB51 and RB51-QAE as well 
as E. coli DH5-α and DH5-α-TOPOE.  Whole cell lysates were used for all species and 
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purified membrane components were obtained for DH5-α and DH5-α-TOPOE.  To 
isolate membrane components for DH5-α and DH5-α-TOPOE, a 5×108 CFU/ ml culture 
was grown overnight at 37°C.  Cells were pelleted and resuspended in .75M sucrose- 
10mM tris.  Lysozyme and EDTA were added to the suspension and the cells were 
pelleted.  The supernatant was drawn off and ultracentrifuged at 60,000 rpm to isolate  
membrane portions.  
2D Gel Analysis 
 Protein samples were cleaned using the Ready Prep 2D Cleanup Kit (BioRad 
Laboratories).  One hundred μl of each lysate was mixed with 300μl precipitating agent 1 
(BioRad Laboratories), then incubated on ice for 15 minutes.  Three hundred μl of 
precipitating agent 2 (BioRad Laboratories) was added and the tubes were centrifuged at 
14,000 rpm for 5 minutes for pellet formation.  The supernatant was removed, 40μl of 
wash reagent 1 (BioRad Laboratories) was added to the pellet, which was centrifuged at 
14,000 rpm for 5 minutes.  Next, 25μl of Ready Prep proteomic grade water (BioRad 
Laboratories) was used to resuspend the pellet.  One milliliter of pre-chilled wash reagent 
2 (BioRad Laboratories) was added with 5μl of wash 2 additive (BioRad Laboratories) 
then vortexed for 1 minute.  Each tube was incubated on ice for 30 minutes, with a 30 
second agitation every 10 minutes during incubation.  The tubes were centrifuged at 
14,000 rpm for 5 minutes to form a pellet.  The pellet was allowed to air dry at room 
temperature then resuspended using 2D Rehydration buffer (BioRad Laboratories).  The 
samples were centrifuged at 14,000 rpm for 5 minutes.  The supernatant was drawn off 
and run on Immobilized pH Gradient (IPG) strips (BioRad Laboratories).   
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 Protein samples were loaded onto a focusing tray and the thawed IPG strips were 
placed gel side down onto each sample.  An Isoelectric Focusing apparatus (IEF) 
(BioRad) was programmed previously according to instruction and the IPG strips were 
allowed to run overnight. Each strip was removed from the IEF, blotted, and transferred 
to an equilibration tray.  The strips were covered with 2 ml Equilibration Buffer I 
(BioRad Laboratories) and placed on a rocker for 15 minutes.  The equilibration step was 
repeated with Equilibration Buffer 2 (BioRad Laboratories).  The strips were blotted then 
rinsed in Tris-Glycine-SDS (TGS) running buffer. Each IPG strip was placed into the 
well of a precast gel cassette (12.5% concentration) using flat pliers until complete 
contact was made between the strip and the bottom of the gel.  A protein size standard 
was loaded and the gels were run at 10mA until the dye front reached the bottom of the 
gel.  The gel was placed in a fixative solution (10% methanol, 7% acetic acid) and rocked 
for 1 hour. The fixative was removed and the gel stained in SYPRO Ruby Stain (BioRad 
Laboratories) overnight.  The stain was removed and the gel was destained for 1 hour.  
The gel was washed 3 times with dH2O and imaged using a UV transilluminator.   
 Comparisons between the gels were made and unique spots excised.  The excised 
spots were placed in 50 ml of sterile dH2O and agitated until dissolved.  The tubes were 
stored at -4°C until sent off for mass spectrometry analysis.  The results of this analysis 
were analyzed using NCBI BLAST to determine similarity to the region E protein.   
Results 
Preliminary Characterization 
 According to BLAST searches, the region E gene was found to have homology 
with a putative hemagglutinin and cell surface proteins found in B. melitensis, B. suis, B. 
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ovis, B. canis, B. ceti and B. pinnipedialis.  Examination of the genes surrounding region 
E on the genome showed coding regions for putative transposases or putative transposase 
subunit proteins upstream, downstream, and overlapping the region E gene (Figure 5), 
indicating that the putative gene is monocistronic and may be a pathogenicity island 
delivered to B. melitensis by horizontal gene transfer.   
Cell Lysate Hemagglutination Assay 
 Sonicated lysates for RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE were used 
in a series of hemagglutination assays using caprine erythrocytes.  Each plasmid, both 
pQAE and TOPOE, were sequenced and the presence of the region E gene in each was 
confirmed.  Each of the lysates were serially diluted in PBS and equalized in density 
using spectrophotometric analysis.  A 1 ml portion of each lysate was centrifuged and the 
supernatant was drawn off and used in a hemagglutination assay.  Caprine erythrocytes 
were washed and a 2% erythrocyte solution was prepared on the day of assay preparation.  
A PBS control was included for both lysate and supernatant assays.  Each assay was 
allowed to incubate at room temperature overnight. 
 None of the lysates from any species or strain showed any differences in 
hemagglutination capabilities.  Each differed from the PBS control because of the 
presence of cellular debris in the well.  A dark button of erythrocytes was seen in each 
well, under the cellular debris.  It was concluded that all of the lysates tested were 
hemagglutination negative.  Buttons were also observed in the assays studying the 
supernatants from each of the lysates, confirming that the supernatants were also 









Map showing the coding regions of the Brucella melitensis 16M genome 1000bp 




























Table 3. Hemagglutination results observed for RB51, RB51-QAE, DH5-α, and DH5-α-
TOPOE using both bovine and caprine erythrocytes. 
 




RB51 ND ND NP NP NP 
RB51-QAE 
HA+ to 1:8 
dilution 
HA+ to 1:16 
dilution NP NP NP 
DH5-α NP NP ND ND ND 
DH5-α-TOPOE NP NP 
HA+ to 1:16 




RB51 ND ND NP ND ND 
RB51-QAE 
HA+ to 1:16 
dilution 
HA+ to 1:32 
dilution NP ND ND 
DH5-α NP NP ND ND ND 
DH5-α-TOPOE NP NP 
HA+ to 1:16 
dilution ND ND 
 
ND None Detected 



























 Broth cultures were prepared for RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE.  
Both strains of RB51 were cultured in brucella broth.  An amount of 45μg/ ml of 
ampicillin was added to the broth culture of RB51-QAE and to a control culture of RB51.   
LB broth was used to culture both strains of DH5-α, and DH5-α-TOPOE.  An amount of 
1μl/ ml of kanamycin was added to the broth culture of DH5-α-TOPOE and to a control 
culture of DH5-α.  A 1 ml portion of each broth culture was centrifuged at high speed and 
the supernatant was used to prepare serial dilutions in PBS for hemagglutination assays.  
The broth cultures were equalized using spectrophotometric data and serial dilutions were 
prepared in sterile PBS.  Fresh preparations of 2% caprine and bovine erythrocytes were 
used. 
 Clarity and size of button were similar across RB51 and RB51-QAE for both 
species of erythrocytes tested.  The only difference appeared to be button color 
differences that corresponded to the presence or absence of region E protein.  The buttons 
observed for the RB51-QAE cultures were dark red in color, which differed from those 
observed for the last 5 dilutions of RB51 and all of the dilutions of PBS, which were a 
lighter red in color.  However, because of the presence of these buttons, all assays for 
both RB51 strains using both caprine and bovine erythrocytes were considered 
hemagglutination negative.  There appeared to be no visible difference between the  
control PBS dilutions and the supernatants from both RB51 and RB51-QAE cultures.  All 
supernatant cultures were considered hemagglutination negative. 
 For cultures of DH5-α and DH5-α-TOPOE, there were no visible differences 
between strains in either color or clarity across both caprine and bovine erythrocyte 
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preparations.  A button was observed for each dilution of culture as well as for each 
sample of supernatant tested.  All DH5-α and DH5-α-TOPOE cultures and supernatants 
were considered hemagglutination negative (Table 3).   
Bacterial Harvests 
 Fresh bacterial lawns of RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE were 
grown on selective media, harvested in sterile PBS, and subjected to hemagglutination 
assays using both caprine and bovine 2% erythrocyte preparations.  RB51 and RB51-
QAE were grown on brucella selective blood agar plates.  Two series of plates were used 
to grow both RB51 strains with one series produced using caprine blood and the other 
produced using blood from a bovine.  Ampicillin was added to the plates used to culture 
RB51-QAE.  DH5-α and DH5-α-TOPOE were grown on LB agar plates.  Kanamycin 
was added to the plates used to culture DH5-α-TOPOE.  The harvests were equalized in 
density according to spectrophotometric analysis.   
 Using caprine erythrocytes, a clear difference was seen between the 
hemagglutination assays for RB51 and RB51-QAE.  Cellular sediment was seen in each 
well across all dilutions for both strains.  A clear demarcation between RB51 cells and 
erythrocytes was observed as a dark ring of erythrocytes atop a light mass of cells across 
dilutions.  For the sediment of RB51-QAE, there was no demarcation between cells and 
erythrocytes.  Instead, a uniform mass was observed for the first 5 dilutions of RB51-
QAE harvests, which were considered hemagglutination positive (Figure 6). 
 Using bovine erythrocytes, similar results in button consistency were seen for 
both RB51 throughout each dilution and for RB51-QAE for the first 4 dilutions.  For this 
reason, the first 4 dilutions of RB51-QAE were considered hemagglutination positive.  
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However, these differences were not as prominent as seen in the caprine erythrocytes.  
For example, even though there was a more uniform grouping of cells for RB51-QAE, 
there was still a hint of a light button present, which was not observed in the assays using 
caprine erythrocytes.   
 Clear differences were observed between the RB51-QAE harvests for across 
caprine and bovine erythrocytes.  The caprine erythrocyte samples for RB51 appear 
similar to the bovine erythrocyte samples for RB51.  However, RB51-QAE in caprine 
erythrocytes shows more hemagglutination properties to a greater extent (1 full dilution) 
than RB51-QAE in bovine erythrocytes.  These results were consistent across groups of 
cells grown on both caprine and bovine blood agar plates (Table 3).   
 Cell harvests for DH5-α and DH5-α-TOPOE performed similarly in 
hemagglutination assays as RB51 and RB51-QAE, respectively.  The same demarcation 
effect between erythrocytes and cells was observed for DH5-α dilutions across both 
caprine and bovine erythrocytes.  The first 4 dilutions of DH5-α-TOPOE harvests 
resulted in a uniform mass of cells with no clear division between both caprine and 
bovine erythrocytes and bacteria.  These first 4 dilutions of DH5-α-TOPOE harvests were 
considered hemagglutination positive for both bovine and caprine hemagglutination  
assays.  There was no clear difference between the assays using bovine and caprine 
erythrocytes for DH5-α and DH5-α-TOPOE (Table 3). 
Protein Characterization using Absorption Assay and 2D Gel Electrophoresis 
 For the absorption analysis assay, serum from goats inoculated with Brucella 
species expressing the region E gene (2308-QAE, RB51-QAE and 16M) was absorbed 





Assay comparing the hemagglutinating capabilities of RB51 and RB51-QAE using 
caprine erythrocytes.   Each sample was subjected to 1:2 serial dilutions made in sterile 
PBS and mixed with 100μl washed caprine erythrocytes. 
 
Row 1: Sterile PBS control 
Row 2: RB51-QAE cell harvests 




























RB51, and 16MΔE).  A unique band was observed on western immunoblots run with the 
serum of goats inoculated with species of Brucella containing the region E gene that was 
not present in those lanes containing the lysates of Brucella species lacking the region E 
sequence.  This band was approximately 74 kD in size, which is the approximately the 
estimated size of the region E putative hemagglutinin protein.  This unique banding was 
seen especially for the RB51-QAE lysates on the immunoblot (Figure 7).  Considering 
that RB51-QAE is a rough strain, this effect may be due to increased exposure of the 
region E protein due to a lack of OPS interference.  
 Lysates of RB51 and RB51-QAE as well as cell membrane isolates of DH5α and 
DH5α-TOPOE, were analyzed using 2D electrophoresis.  The resultant RB51 and RB51-
QAE gels were compared and a unique spot could not be identified (Figure 8).  Because 
of the complexity of the whole cell lysates, outer membrane fractions of DH5α and 
DH5α-TOPOE  were collected and subjected to 2D analysis (Figure 9).  A single spot 
with an isoelectric point and molecular weight of the region E hemagglutinin was 
identified in DH5α-TOPOE, but mass spectrometric analysis of the sopt failed to confirm 
a peptide map that matched. 
Discussion 
 Genomic comparisons have been made between the region E protein and a 31kD 
outer membrane protein found on the surface of B. suis (omp31), which has been 
described as a cell surface heme-binding protein.  Hemagglutination assays were 
 prepared to test the hemagglutination ability of RB51 versus RB51-QAE.  It was 
expected that RB51-QAE would have an increased effect on hemagglutination, as the  
region E gene encodes for a putative hemagglutinin.  Assays showed that at high 
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Western Blot run with absorbed serum from a goat inoculated with RB51-QAE.  The 
serum was absorbed using RB51 previously.  The unique banding pattern seen in the lane 
containing RB51-QAE lysates indicates that the region E protein is capable of eliciting a 
specific humoral response in goats when expressed by RB51.  The unique bands are seen 
between approximately 60 and 80 kD, according to the size standard in lane 1.  Because 
the estimated size of the region E protein is 68.94 kD, it is proposed that one of these 
unique bands (designated by the red box) indicates antibodies specific for the region E 
protein.  The bands are observed in lanes 3 and 7 as well, but were too faint to appear 
using our best imaging techniques.  This may be due to phenotypic differences between 
16M and 2308-QAE as compared to RB51-QAE. 
 
The lane order is as follows: 
 
1.  Size standard marker 
2.  B. abortus 2308 
3.  B. abortus 2308-QAE 
4.  B. abortus RB51 
5.  B. abortus RB51-QAE 
6.  B. melitensis 16MΔE 
7.  B. melitensis 16M 
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2D image of B. abortus RB51 
 





2D gel images taken of B. abortus RB51 and B. abortus RB51-QAE for the purpose of 
identifying unique proteins produced by RB51-QAE.  The complexity of the 2D gel 
images of B. abortus RB51 and B. abortus RB51-QAE precluded the identification of a 
unique spot for RB51-QAE that corresponded to the region E hemagglutinin.  The top 






2D image of DH5α isolated membrane 
 
2D image of DH5α-TOPOE isolated membrane 
 
Figure 9. 
2D gel images were taken of E. coli DH5α and DH5α-TOPOE for the purpose of 
identifying unique proteins produced by DH5α-TOPOE.  The top image is of the 2D gel 
run with DH5α membrane isolates and the bottom image is of DH5α-TOPOE membrane 
isolates.  The unique protein identified on the DH5α-TOPOE gel is outlined in red and 






numbers, presence of the region E gene in the genome of RB51-QAE caused positive 
hemagglutination in a 2% bovine and caprine erythrocyte solutions, whereas RB51 did 
not.  Furthermore, a higher incidence of hemagglutination was observed when subjected 
to the assay using erythrocytes from goat blood, as compared to blood erythrocytes from 
a cow.  Also, a greater incidence of hemagglutination was seen when the RB51-QAE 
tested was grown on media using goat blood rather than cow blood.  This suggests that 
not only is the region E protein a hemagglutinin, but it is also a host-specificity factor.  
The hemagglutination assays for E. coli DH5α and DH5α-QAE were similar in that 
positive hemagglutination was noted for the region E mutant, and not for the parental 
strain.  No agglutination was observed using cell broth culture supernatant for any of the 
bacterial strains tested, suggesting that the hemagglutinating factor was not excreted from 
the cell, but present on the surface.  Further studies would be needed on a proteomic level 
to further characterize the cellular location, hemagglutination and host specificity 
capabilities of the region E protein.   
  The absorption assay performed indicated unique bands on western 
immunoblots run with serum from goats inoculated with various strains of brucella both 
containing and lacking the region E gene sequence.  These unique bands, at 
approximately 74kD, are of the approximate size of the putative hemagglutinin encoded 
by the region E sequence.  These bands were not present in the blot lanes for those strains 
that did not contain region E.  Specifically, this suggests that the immunogenic protein 
produced by 2308-QAE, RB51-QAE, and 16M is recognized by the goat immune system 
and is not produced by 2308, RB51, and 16MΔE.  This indicates that the putative 
hemagglutinin may increase the immunogenic capabilities of RB51 in the host animal, 
 86
inducing the production of anti-region E protein antibodies.  This is another finding that 
supports the proposal that RB51-QAE would be an improved vaccine candidate when 
compared to RB51. 
 There was a measureable difference in hemagglutination in isolates carrying the 
region E clone, but the protein could not be identified in the 2D analysis.  This could be 
due to many factors, such as the region E protein being the same size and isoelectric point 
as another RB51 protein or cluster or proteins, which would make the region E protein 
indistinguishable from the other proteins.  The 2D analysis of the pure protein would be 
beneficial, but the exact size and isoelectric point of the region E protein are estimated at 




























 The control of brucellosis as a worldwide disease relies upon effective 
vaccination in animals and proper diagnostic testing.  Human brucellosis, most often 
contracted through interaction with infected animals, remains problematic in many 
countries around the world.  Because there is no vaccine for human use, control of human 
brucellosis depends on accurate diagnosis and proper treatment.  Currently, diagnosis of 
brucellosis in humans involves serologic testing and confirmation through blood culture.  
Although this is the diagnostic gold standard, there are issues involved with these 
techniques that may hinder proper diagnosis.  Serologic tests are subject to false-positive 
results due to cross reacting antibodies and confirmation through culture may take weeks, 
as Brucella spp. are slow growing organisms.   
 Methods of detection utilizing the polymerase chain reaction (PCR) are being 
investigated for improved diagnosis.  A reliable PCR technique would be quicker, easier, 
and more affordable than current procedures while eliminating the possibility of false 
positive reactions.  Current research in this area, however, has been inconsistent.  Results 
differ based on biological sample type tested, DNA isolation methods used, and variation 
in testing schedules. 
 In this study, the limit of detection of B. abortus 2308 and B. melitensis 16M was 
examined using the Baily, Omp25, and ORF-944 Brucella-specific primer sets for 
conventional PCR amplification and visualization using agarose electrophoresis.  These 
laboratory strains were diluted in fluid samples that may be taken for diagnostic purposes, 
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including blood, plasma, serum, and urine.  Optimization of DNA isolation technique and 
thermalcycler protocols was also examined.  The results of this study can aid in 
continuing efforts to develop a reliable PCR technique for the purpose of improved 
diagnosis of human brucellosis and increased control of the disease worldwide. 
Materials and Methods 
 
Bacterial Strains  
 
 B. abortus 2308 and B. melitensis 16M were studied in these PCR assays.  
Bacteria were obtained using stocks of 1x1010 (2308) and 1x1011 (16M) colony forming 
unit (CFU) concentrations and chloroform-killed.  These cells were then serially diluted 
to 1x101 CFU in sterile H2O, whole blood, plasma, serum, or urine and subjected to either 
direct PCR amplification or DNA isolation and quantification. 
 One assay for the limit of detection of the region E gene sequence using the 
region E primer set was performed using B. abortus RB51-E and 16M as template.  For 
this assay, bacteria were obtained as described above from previously prepared stocks of  
1x109 CFU for RB51-QAE and 1x1011 CFU for 16M.  These cells were serially diluted 
ten-fold to 1x101 CFU in sterile H2O and subjected to PCR amplification using the region 
E ORF-944F and ORF-944R primers following DNA isolation and quantification. 
DNA Isolation 
 Two separate DNA isolation protocols were performed on the cellular dilutions 
made in whole blood.  The first protocol used was outlined in the Qaigen DNeasy Blood 
and Tissue Handbook (Qaigen, Inc.) using the Qaigen DNeasy Blood and Tissue Kit 
(Qaigen, Inc.).  The second protocol used is the standard protocol used in lab, which also 
utilizes the Qaigen DNeasy Blood and Tissue Kit (Qaigen, Inc).   
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 The first DNA isolation protocol was performed by mixing 50μl of a blood 
dilution with 180μl buffer ATL (Qiagen, Inc.).  A volume of 20μl of proteinase K was 
added to the mixture, vortexed, and placed in a shaking water bath at 55°C for 1 hour.  
Two hundred μl of buffer AL was added and the tubes were placed in a 70°C heating 
block for 10 minutes.  Two hundred microliters of 100% ethanol was added and the 
samples were placed into a DNeasy spin column.  A volume of 500μl of buffer AW1 was 
added to the sample and centrifuged at 8000rpm for 1 minute.  Five hundred μl of buffer 
AW2 was added and the samples were spun at 14,000rpm for 3 minutes.  The spin 
column was placed into a clean 1.5 ml centrifuge tube, 200 μl of buffer AE was pipetted 
onto the membrane of the spin column and allowed to incubate at room temperature for 1 
minute.  The samples were centrifuged at 8000 rpm for one minute.  A second elution 
step was repeated.  The resultant isolated DNA was stored at 20°C until use. 
 The second DNA isolation protocol was performed by pipetting 50μl of a blood 
dilution sample into a 1.5  ml centrifuge tube containing 20μl of proteinase K (Qiagen, 
Inc.).  The volume was adjusted to 220μl with sterile PBS (Sigma Chemical Co.).  A 
200μl volume of buffer AL (Qiagen, Inc.) was added to the tube, mixed by vortexing, 
then incubated with agitation at 56°C for 10 minutes.  Next, a volume of 200μl of 100% 
ethanol was added, the mixture was loaded into a DNeasy spin column (Qiagen, Inc.), 
and centrifuged at 8000 rpm for 1 minute.  Five hundred μl of buffer AW1 (Qiagen, Inc.) 
was added and the column was centrifuged at 8000rpm for an additional minute.  Next, 
500μl of buffer AW2 (Qiagen, Inc.) was added to the spin column and the samples were 
centrifuged at 14,000rpm for a period of 3 minutes.  The spin column was placed into a 
clean 1.5 ml microcentrifuge tube and 200μl of buffer AE (Qiagen, Inc.) was added to the 
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tube and allowed to incubate at room temperature for 1 minute.  A second elution step 
was repeated for maximum DNA collection.  The tube was centrifuged for 1 minute at 
8000rpm and the resultant flow-through was stored at 20°C until use. 
 The remaining groups (dilutions prepared in sterile H2O, plasma, urine, and 
serum) were subjected to DNA isolation using only the first DNA isolation protocol, as it 
proved to be a better technique for maximum isolate DNA collection.   
Primer Selection and Preparation 
 The Omp25 primer set was designed using the Omp25 gene sequence of B. 
abortus, which is highly conserved across Brucella spp., by Phillipe de Wergifosse et al. 
(de Wergifosse et al., 1995).  The first set of primers selected targets the Omp25 gene and 
are designated Omp25F (5’ –GTTCCGGCTCCGGTTGAAGTA -3’) and Omp25R (5’ – 
CGCGGATATCCTGCGTGTC -3’).  The second set of primers were specific for 31 kDa 
B. abortus antigen and designed to detect both B. abortus and B. melitensis (Baily et al., 
1992).  The Baily primers were designated B4 (5’ – TGGCTCGGTTGCCAATATCAA- 
3’) and B5 (5’- CGCGCTTGCCTTTCAGGTCTG- 3’).  While both primer sets are used 
to detect B. abortus and B. melitensis DNA, neither will differentiate between the two 
species.  A third set of primers was used for a limit of detection assay targeting the region 
E gene sequence in 16M and RB51-QAE.  The ORF-944F and ORF-944R primers were 
used as previously described.  Each primer set was synthesized by Integrated DNA 
technologies, Inc. (Coralville, IA) and re-suspended using PCR grade H2O upon arrival.   
Limit of Detection  
 Preliminary studies were performed using previously isolated DNA from B. 
abortus 2308, B. abortus RB51-QAE and B. melitensis 16M.  DNA was quantified using 
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the GE Healthcare RNA/DNA Calculator Spectrophotometer Model Gene Quant Pro 
(Amersham Bioscience).  A series of 1:10 dilutions were prepared in sterile H2O and 
subjected to PCR using the Omp25 and Baily primer sets.  A second set of 1:10 dilutions 
was made for both Brucella species, but using known concentrations.  Specifically, a 
starting concentration of 1x1011 CFU/ ml of B. melitensis 16M and a 1x1010 CFU/ ml 
starting concentration of B. abortus 2308 were both diluted ten-fold to a concentration of 
1×101 CFU/ ml in sterile H2O. These preparations were also subjected to PCR using both 
primer sets.  Using the same 16M dilutions (1x1011 CFU/ ml to 1×101 CFU/ ml in sterile 
H2O) and a set of similarly prepared RB51-QAE dilutions (1x10
11 CFU/ ml to 1×101 
CFU/ ml in sterile H2O), a limit of detection assay was performed using conventional 
PCR and the region E ORF-944 primers.  The resultant amplifications were subjected to 
agarose gel electrophoresis and visualized as previously described. 
Bacterial Sample Preparation 
 A total of 5 experimental groups were prepared for PCR analysis based on the 
fluid used to dilute each of the samples.  The first group studied the PCR detection 
capabilities of the Omp25 and Baily primers on 2308 and 16M using colony forming 
units (CFU) as template and isolated DNA diluted in sterile H2O.  The detection 
capabilities of the ORF-944 primers on RB51-QAE and 16M using DNA isolated from 
CFU dilutions in sterile H2O was also studied.  For all groups, samples were prepared 
following chloroform killing.  Serial dilutions of 1:10 were prepared in sterile H2O for 
each Brucella species and each dilution was subjected to PCR individually.  A 1.0 μl 
portion was used as PCR template and the rest subjected to DNA isolation.  The results 
from this first group were used as a control for comparison of the remaining four groups.   
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 The next group consisted of chloroform killed CFUs from both 16M and 2308 
diluted in whole blood.  A series of 1:10 dilutions were made as described above with 
both 2308 and 16M, but using whole blood obtained from an infection-free animal in the 
place of sterile H2O.  Similarly, a 1.0 μl sample of each dilution was used directly for 
PCR and the rest underwent DNA isolation.   
 The remaining groups were prepared in a similar fashion, except using plasma, 
urine, or serum in the place of whole blood.  Each group was subjected to PCR using 
CFU as template and to DNA isolation to use for PCR as a DNA template.   
PCR Technique 
 PCR was performed as described previously using the FailSafe PCR System with 
2X G Premix (Epicentre Biotechnologies) and a MyCycler Personal Thermal Cycler 
(BioRad Laboratories).  For amplification using the Omp25 primers, template DNA was 
subjected to an initial denaturation step for 4 minutes at 95°C.  Next, 34 cycles were 
completed with denaturation at 95°C  for 30 seconds, primer annealing at 65°C  for 30 
seconds, and elongation at 72°C  for 2 minutes.  A final elongation stage of 72°C was 
performed for 10 minutes (Edmonds 2001).  For amplification of the Baily primers, 
template DNA was subjected to an initial denaturation step for 5 minutes at 95°C.  Then 
40 cycles were completed with denaturation at 90°C for 1 minute, primer annealing at 
60°C for 30 seconds, and elongation at 72°C for 1 minute.  A final elongation stage of 
72°C was performed for 7 minutes.  A second series of PCR assays were performed using 
the same PCR preparations, but elongating each of the primer thermal cycler protocols by 
5 cycles in an attempt to optimize amplification.  This brought the total number of cycles 
to 39 for the Omp25 protocol and 45 for the Baily protocol for these asssays (Baily 
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1992). For amplification using the ORF-944 primers, the thermal cycler protocol was 
performed as previously described.  The resultant PCR amplifications were subjected to 
Agarose gel electrophoresis for visualization as previously described. 
Results 
DNA quantification 
 Using previously made B. abortus 2308 and B. melitensis 16M stocks, a series of 
nine 1:10 dilutions (ranging from approximately 1 μg/μl to 1×10-8 μg/μl) were prepared 
for each in 100μl sterile H2O.  The standard laboratory DNA isolation protocol described 
previously was used to isolate DNA from each dilution.  The DNA isolates of only 100% 
concentration were quantified, as any dilutions were not quantifiable by the equipment 
used.  For the pure 2308 sample, a DNA quantity of 0.87 μg/μl was measured.  For the 
pure 16M sample, a quantity of 0.94 μg/μl was measured.  The RB51-QAE sample 
yielded a DNA quantity of 0.4x102 μg/μl. 
 The PCR amplification performed using the Omp25 primers and 16M DNA 
provided a limit of detection of 1×10-4.05 , or 1:1000, of the original sample, which is  
approximately 9.35x10-5 μg/μl.  The PCR amplification performed using the Omp25 
primers and 2308 DNA provided a limit of detection of approximately 8.72x10-6 μg/μl, 
which is a 10-5 dilution of the original sample. 
 The PCR amplification performed using the Baily primers and 16M DNA 
provided a limit of detection of 1×10-7.4 of the original dilution, which is approximately 
9.35x10-8 μg/μl.  The PCR amplification performed using the Baily primers and 2308  
DNA provided a limit of detection of 1×10-7 of the original dilution, which is 
approximately 8.72x10-8 μg/μl (data not shown). 
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 Using the ORF-944 primers and 16M DNA, a limit of detection was found to be 
approximately 9.35x10-5 μg/μl.  For the ORF-944 primers ad 2308 DNA, a limit of 
detection was found at 4.0x10-6 μg/μl (Figure 10). 
Thermal Cycler Protocol Optimization 
 In an attempt to optimize the standard thermal cycler protocols for both the Baily 
and Omp25 primers, preliminary PCR assays were performed using the standard number 
of amplification cycles for each primer set and an elongated protocol using 5 additional 
amplification cycles for each primer set.  It was observed that the elongated protocol 
provided greater detection capabilities for both 16M and 2308 CFU and DNA than the 
standard thermal cycler protocol for both primer sets.  Specifically, for the PCR assays 
using both 2308 and 16M CFU as template, the original thermal cycler protocol provided 
a limit of detection at 1×108 CFU/ ml and the elongated thermal cycler protocol provided 
a limit of detection at 1×105 CFU/ ml (for both 16M and 2308 using both primer sets).  
Because of these results showing a 1000-fold increase in detection, the elongated  
protocols were used for these PCR experiments and would be recommended for further 
experimentation on the detection of Brucella cells using conventional PCR. 
B. abortus 2308 and B. melitensis 16M in Sterile H2O 
 The first series of PCR were performed using DNA isolated from a known 
amount of colony forming units (CFU) of both 2308 and 16M as template, as well as 
using CFU as template using the Omp25 and Baily primers for both.  The CFU were  
diluted in sterile H2O for a series of ten 1:10 dilutions from the original 1x10
10 




Figure 10.   
 
Agarose gel electrophoresis of the PCR amplification products of 16M DNA serially 
diluted in sterile H2O using the ORF-944 region E primers. 
 
The lane order for the 16M gels is as follows: 
 
 1.  1kb size standard marker 
 2.  Positive RB51-QAE control 
 3.  Negative control 
 4-9. RB51-QAE DNA concentrations from 107 CFU/μl – 102 CFU/μl 














concentration of 16M CFU (both diluted to a final concentration of 1×101 CFU).  A 1.0 
μl sample of each CFU dilution was subjected to PCR using both primer sets.  The rest of 
the dilutions underwent the standard lab DNA isolation procedure described and the 
resultant DNA isolates were subsequently amplified by PCR using both primer sets.   
 Using the Omp25 primers and 2308 CFU, positive identification was possible to 
the 103 2308 CFU/μl H2O.  Using the Baily primers and 2308 CFU, positive 
identification was also possible to the 103 2308 CFU/μl H2O.   Faint banding seen on the 
gel in dilutions greater than 103 2308 CFU/μl H2O was rare and this was most likely due 
to a contamination error.  Using both the Omp25 and Baily primers and 16M CFU, 
positive identification was possible to the 1x103 16M CFU/μl H2O. There were no faint 
bands witnessed in dilutions greater than 1x103 16M CFU/μl H2O like those seen for 
2308 (Figure 11).  
 Using the Omp25 primers and 2308 DNA isolates, positive identification was 
possible for every dilution tested (1x109-1x1001 2308 DNA/100μl H2O).  The same was 
observed using the Baily primers and 2308 DNA isolates.  For the DNA isolated from 
16M, both the Omp25 and Baily primers produced positive banding for all dilutions 
(1x1010-1x1001 16M DNA/100μl H2O) (Figure 12).  Contamination was ruled out for all 
PCR reactions due to the absence of a band in the negative control lane.   
DNA Isolation Techniques for Whole Blood 
 Two DNA isolation techniques were tested for optimal DNA recovery from 
samples of whole blood spiked with B. abortus 2308 and B. melitensis 16M.  The first 







                             
 








Results of the agarose gel electrophoresis of the PCR amplification products of 2308 and 
16M in sterile H2O using CFU as template and both primer sets. 
 
The lane order for the 16M gels is as follows: 
 
 1.  1kb size standard marker 
 2.  Negative control 
 3-13. 16M CFU concentrations from 109 CFU/μl – 0.1 CFU/μl 
 
The lane order for the 2308 gels is as follows: 
 
 1.  1kb size standard marker 
 2.  Negative control 
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Figure 12.  
 
Agarose gel electrophoresis of the PCR products of DNA isolated from ddH2O dilutions 
of 2308 using the Omp25 primer set.  These results were consistent with those observed 
for the amplification of 2308 DNA using the Baily primers and for the amplification of 
16M DNA across both primer sets as well.   
 
The lane order for the 16M omp25 and Baily gels is as follows: 
 1.  1kb Marker 
 2.  Negative control 
 3-12.  DNA isolation concentrations from 108 CFU/μl – 1 CFU/10μl 
 
The lane order for the 2308 omp 25 and Baily gels is as follows 
 1.  1kb Marker 
 2.  Negative control 






second was the suggested procedure for DNA isolations from samples of whole blood.  
Both procedures were taken from the Qiagen DNeasy kit manual. 
 The first DNA isolation procedure provided a greater output of isolated DNA, as 
shown by higher detection capabilities when subjected to PCR amplification.  As a result, 
the remaining DNA isolations performed utilized the standard lab procedure first 
described.   
B. abortus 2308 and B. melitensis 16M in Whole Blood  
 Serial 1:10 dilutions were prepared similarly to the first series of PCR assays, but 
using whole blood from a brucellosis negative goat in the place of sterile H2O.  The CFU 
were diluted in whole blood for a series of ten 1:10 dilutions from the original 1×1010 
concentration of 2308 CFU and eleven 1:10 dilutions from the original 1×1011 
concentration of 16M CFU.  The dilutions underwent both the first and second DNA 
isolation procedures described and the DNA isolates were amplified by PCR using both 
primer sets.  The DNA examined in these experiments was obtained through DNA 
isolation of whole blood and CFU mixtures and at no time was DNA alone added to any 
dilution of whole blood. 
 Using whole blood to dilute B. abortus 2308 and B. melitensis 16M CFU as 
template for PCR using both primer sets proved unsuccessful for detection in any of the 
dilutions tested.  Elongation of thermal cycler protocols for both Omp25 and Baily 
primers did not improve detection and no positive banding was observed on any of the 
gels run for these assays (data not shown).    
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 The standard lab procedure for DNA isolation provided greater detection 
capabilities than using CFU alone when testing whole blood dilutions spiked with 2308 
and 16M.  Using the B. melitensis 16M DNA isolated from CFU in whole blood, the 
Baily primers provided a limit of detection down to the 1x103 original CFU dilution.  The 
Omp25 primers were not as effective for B. melitensis 16M DNA and provided positive 
banding to the 1x104 original CFU dilution when diluted in whole blood.  For the B. 
abortus 2308 DNA isolates, both primer sets provided positive banding to the 1x102 
original CFU dilution, but this band was extremely faint.  For this reason, it was 
concluded that the limit of detection for B. abortus 2308 DNA isolated from CFU in 
whole blood was seen at 1x103 original CFU dilution (Figure 13).   
 The second procedure for DNA isolation was not as effective as the standard 
procedure described above.  For the 16M DNA isolates, both Omp25 and Baily primers 
were able to provide a limit of detection of 1x106 original CFU concentration.  For the 
2308 DNA isolates, both Omp25 and Baily primers provided positive banding up to the 
1x106 original CFU concentration.  However, the band seen for a 1x106 CFU 
concentration of B. abortus 2308 DNA was extremely faint for both primer sets, and was 
not considered sufficiently visible for an absolute positive result.  For this reason, it was 
concluded that the limit of detection for B. abortus 2308 DNA using the standard lab 
protocol for DNA isolation is 1x107 original CFU concentration in whole blood for both 
Omp25 and Baily primer sets. 
 Both DNA isolation procedures performed for the 2308 and 16M dilutions in 
whole blood exhibited inferior detection capabilities when compared to those observed 
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Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 2308 
and 16M CFU in whole blood using the Baily and Omp25 primer sets.   
 
The order of the lanes is as follows: 
 
 1. 1kb size standard marker 
 2.  Negative control 








procedures that red blood cell lysis products tend to block flow through a spin column, 
which may have inhibited the amount of DNA isolated from these samples.  For this 
reason, whole blood would not be considered as an ideal fluid for the detection of 
Brucella cells, if present in the sample (Not pictured).  
B. abortus 2308 and B. melitensis 16M in Plasma 
 Serial 1:10 dilutions were prepared in the same way as the whole blood series of 
PCR assays, but using plasma from a brucellosis negative goat in the place of blood.  The 
B. melitensis 16M and B. abortus 2308 CFU were diluted similarly.  The dilutions 
underwent only the first standard DNA isolation procedure described and the DNA 
isolates were amplified by PCR using both primer sets.   
 For the PCR amplification of B. melitensis 16M CFU, a limit of detection was 
observed at a concentration of 1x105 CFU using both the Omp25 and Baily primers.  
Using B. abortus 2308 CFU as template for both primer sets yielded a limit of detection 
of 1x105 CFU (Figure 14).   
 Amplification of DNA isolated from plasma dilutions yielded positive detection 
in both species of Brucella, in all dilutions, using both primer sets. No contamination was 
detected, as the negative control lane did not produce banding.  Based on these results, it 
would be possible to detect DNA isolated from CFU of 16M or 2308, if present, in a 
sample of plasma using the Omp25 and Baily primers for conventional PCR (Figure 15). 
B. abortus 2308 and B. melitensis 16M in Serum 
 The PCR assays for serum spiked with 2308 and 16M CFU provided results 
similar to those for 2308 and 16M CFU dilutions in sterile H2O for both primer sets.  
Detection of CFU diluted in serum yielded a limit of 1x103 CFU/μl in both 16M and  
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Figure 14.   
 
Results of the agarose gel electrophoresis of the PCR amplification products of 2308 and 
16M in plasma using CFU as template and both primer sets. 
 
The lane order for the gels is as follows: 
 
 1.  1kb size standard marker 
 2.  Negative control 
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Figure 15.  
 
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M  
and 2308 CFU in plasma using the Baily and Omp25 primer sets.  Detection is possible 
in every dilution.   
 
The order of the lanes for the Omp25 gels is as follows: 
 
 1. 1kb standard size marker 
 2.  Negative control 
 3-11. DNA isolation concentrations from 107 CFU/μl –1 CFU/10μl   
 
The order of the lanes for the Baily gels is as follows: 
 
 1. 1kb standard size marker 
 2.  Negative control 






2308 using both Omp25 and Baily primers (Figure 16).  DNA isolated from serum 
dilutions yielded positive detection following PCR amplification in all 16M and 2308 
dilutions  (1x109-1x101 original CFU concentration) using both primer sets (Figure 17).   
These results show that it would be possible to detect 16M and 2308 CFU, if present, in a 
serum sample using DNA isolation and conventional PCR using the Omp25 and Baily 
primers. 
B. abortus 2308 and B. melitensis 16M in Urine 
 The PCR assays for urine spiked with 2308 and 16M CFU provided results 
similar to those for 2308 and 16M CFU dilutions in sterile H2O.  Specifically, DNA 
isolations performed on 2308 and 16M CFU diluted in urine provided positive banding in 
every dilution (1x109-1x101 original CFU concentration) using both primer sets (Figure 
18).  Using urine spiked with 2308 and 16M CFU as direct template for PCR resulted in 
positive visual identification up to the 1x105 original CFU dilution (1×103 CFU/μl) using 
both primer sets, which is identical to the results observed using 2308 and 16M CFU 
diluted in sterile H2O (Figure 19).DNA isolations performed using urine dilutions of 
2308 and 16M provided complete detection, with banding in every dilution across both 
primer sets.  With these results, it would be possible to detect Brucella CFU in urine, if 
present, using the Omp25 and Baily primers and conventional PCR techniques following 
the isolation of DNA from the sample. 
Discussion 
 
 This is the first known study to investigate the limit of detection when testing 
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Figure 16.  
 
Agarose gel electrophoresis of the PCR products of 16M and 2308 CFU dilutions in 
serum using the Omp25 and Baily primer sets.  This limit of detection was consistent 
across both species and primer sets. 
 
The order of the lanes is as follows: 
 
 1. 1kb standard size marker 
 2.  Negative control 
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Figure 17.  
 
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M 
and 2308 CFU in serum using the Baily and Omp25 primer sets.  Detection is possible in 
every dilution.   
 
The order of the lanes for every gel is as follows: 
 
 1. 1kb standard weight marker 
 2.  Negative control 
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Agarose gel electrophoresis of the PCR products of 16M and 2308 CFU dilutions in urine 
using the Baily and Omp25 primer sets.  This limit of detection was consistent across 
both species and primer sets. 
 
The order of the lanes for each gel is as follows: 
 
 1. 1kb standard weight marker 
 2.  Negative control 
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Figure 19.   
 
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M  
and 2308 CFU in urine using the Omp25 and Baily primer sets.  Detection is possible in 
every dilution.   
 
The order of the lanes is as follows: 
 
 1. 1kb standard size marker 
 2.  Negative control 












what the content of bacteria is in an actual case sample at different stages of infection, 
and further investigation would be needed to examine these quantities. 
 The results of each bodily fluid assay were compared to a control study performed 
in sterile H2O using both B. melitensis 16M and B. abortus 2308 DNA isolations and 
both primer sets.  Detection was possible for DNA isolations from concentrations of each 
species from 1x1010 CFU/ ml through 1x101 CFU/ ml for the PCR assays using known 
concentrations of cells.  An assay was performed using just CFU as template for PCR 
(without DNA isolation) and the limit of detection for each species using each primer set 
was observed at 1x105 CFU/ ml.  For the quantified DNA isolated from an unknown 
concentration of cells, a limit of detection for 16M using the Omp25 primers was found 
to be 9.35x10-5 μg/μl and the limit of detection for 2308 using the Omp25 primers was 
found to be 8.72x10-6 μg/μl. For the quantified DNA isolated from an unknown 
concentration of cells, a limit of detection for B. abortus 2308 using the Baily primers 
was found to be 8.72x10-8 μg/μl and the limit of detection for B. melitensis 16M using the 
Baily primers was found to be 9.35x10-8 μg/μl. These preliminary findings were used to 
compare each of the following assays to determine the effect of each bodily fluid on 
DNA isolation and PCR amplification on detection capabilities using conventional PCR.   
 A limit of detection assay was also performed for the ORF-944 region E primers 
for both 16M and RB51-QAE.  This assay produced results similar to those observed for 
the Omp25 primers for 16M and the limit of detection for RB51-QAE (4.0x10-6 μg/μl ) 
was similar to the limit of detection for 2308 using the Omp25 primers (8.72x10-6 μg/μl).  
Based on these findings, it can be assumed that the detection of RB51-QAE using the 
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ORF-944 primer set may be comparable to the limit of detection findings for 2308 using 
the Omp25 primer set in the following experiments. 
 The optimization of thermal-cycler protocols has been a standard procedure for 
many preliminary PCR assays, especially those using new primer sets.  The addition of 5 
cycles to each protocol increased amplification to a degree that improved detection 
capabilities significantly.   The following results are based on the elongated thermal-
cycler protocol. 
 Whole blood is used for culturing assays, and for this reason was the first fluid 
tested in this study.  It is easy to obtain through non-invasive procedures from humans or 
animals, and animal slaughter is not required.  However, there are several drawbacks to 
using whole blood for PCR amplification of pathogen DNA.  First, the erythrocytes 
present in a whole blood sample interfere with standard DNA isolation techniques using a 
spin column.  The RBCs present in the sample can clog the spin column, inhibiting 
efficient collection and reducing the amount of DNA present in the final isolate volume.  
Second, some components of whole blood, such as hemoglobin, can inhibit amplification 
by PCR.   
 Whole blood was not found to be an optimal candidate for detection of Brucella 
in a blood sample.  Using CFU of B. abortus 2308 and B. melitensis 16M in whole blood 
as template for PCR amplification was not detectable using neither primer set in any of 
the diliutions tested.  For DNA isolated from whole blood dilutions, the limit of detection 
was found at 1x103 CFU/ ml for 2308 using both primer sets and for 16M using the Baily 
primers.  The limit of detection for B. melitensis 16M using the Omp25 primers yielded a 
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limit of detection at 1x104 CFU/ ml.  All results for DNA isolated from whole blood 
dilutions show decreased detection capability when compared to controls.   
 The differences between procedure 1 and procedure 2 for DNA isolation from 
whole blood provided an insight into the limitations of the Qiagen kit used.  The main 
difference between the two is that the lab procedure generally used employed a greater 
number of cell lysis buffers for a greater period of time.  Furthermore, a larger sample 
could be examined using the laboratory technique and thus, a greater final volume of 
Brucella-specific DNA could be obtained for study.   
 Plasma was chosen for investigation because plasma samples contain the buffy 
coat, which is a layer of white cells found between the erythrocytes and plasma layers in 
an anti-coagulation collection tube after settling of whole blood.  Because Brucella are 
sequestered into the macrophages for replication, studying this layer in plasma is of 
importance.  Plasma is a more fluid substance that generally does not interfere with DNA 
isolation techniques.  As with blood, it is also easy to obtain through non-invasive 
procedures.  Detection of B. melitensis 16M CFU was decreased to 1x107 CFU/ ml in 
plasma when compared to controls.  Although there still remain PCR-inhibiting factors in 
plasma, there are far fewer than when compared to whole blood.  Detection of Brucella 
CFU in plasma was similar to controls and detection of DNA isolated from plasma  
dilutions provided detection in all dilutions studied across both species and primer sets.  
This provides evidence that plasma is an acceptable fluid for the use of Brucella cellular 
detection when subjected to DNA isolation. 
 Serum has been tested widely in PCR investigations and thus, has been examined 
here.  The issue with using serum to diagnose brucellosis is that bacteria are largely 
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absent from the serum following the bacteremic stage of infection.  However, serum does 
not appear to inhibit DNA isolation and the PCR-inhibitors found within this substance 
are minimal.  The assay exploring the detection capabilities of the Omp25 and Baily 
primers of 16M and 2308 in serum produced results similar to those seen in the control 
group and in the plasma group.  Specifically, a limit of detection was observed at 1×103 
CFU/μl for CFU and detection of isolated DNA was positive throughout every dilution 
for both species of Brucella using both primer sets.  This suggests that serum has minimal 
inhibitions to DNA isolation and PCR amplification and it would be possible to detect 
Brucella cells, if present, in a serum sample using conventional PCR. 
 Urine, even when concentrated, appeared to have the least inhibiting effects in 
both DNA isolation and PCR, although crystal in urine have been shown to be inhibitive 
to PCR in the past.  The assays performed with urine dilutions provided results similar to 
controls.  DNA isolation provided complete detection in every dilution across both 
species and primer sets.  Urine has been examined in previous studies for the detection of 
Brucella species by PCR.  However, only two species of Brucella are shed in the urine 
and neither is of any real threat to humans.  Nevertheless, practical applications may be 
potentially applied in the diagnosis of animals.  
` Ultimately, plasma, subjected to DNA isolation, is the best candidate for detection  
of Brucella cells from a blood sample.  Whole blood was found to be inhibitive of both 
DNA isolation and PCR amplification.  Brucella cells may not be present in the serum 
following bacteremia and thus, there may be no CFU present for detection using PCR at 
various stages of infection.  Urine was the most efficient fluid in PCR assays and 
provided results most similar to the control groups, but may be unconventional for 
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practical applications.  Furthermore, plasma contains the buffy coat layer, where Brucella 
cells may reside within macrophages.  DNA isolation provided superior detection when 
compared to using CFU as template for all groups tested.  Although this procedure takes 
longer and requires more cost than using CFU alone, using CFU as template is not a 
feasible method of accurate detection.  Another factor to consider is the stage of infection 
at which the blood sample is taken.  For example, detection may be capable in serum if 
taken while the subject or animal is bacteremic, otherwise Brucella cells may not be 
present for detection.  Periodic testing may also be an optimal route for the positive 
identification of brucellosis in suspect infections.   
 These experiments show that in optimal conditions, it is possible to positively 
identify Brucella present in a blood or urine sample using conventional PCR as a 
diagnostic tool.  Because this is the first series of experiments known to be performed to 
study the limit of detection capable when using bodily fluids, this information can be of 
great importance in furthering studies on detection of Brucella in a clinical setting using 
PCR.  If a reliable PCR technique, using either conventional or Real-Time methods, 
could be implicated in endemic countries, diagnosis capabilities would be greatly  
improved in both animals and humans.  Not only would diagnosis be performed up to  
four times more quickly, but the tests developed may be more sensitive as well.  Further 
studies are needed to fully develop an optimal and reliable PCR technique for such 
purposes are ongoing. 







SUMMARY AND CONCLUSIONS 
 
 To better understand the role of a pathogen in disease, it is important to identify 
and examine its virulence factors on both a genetic and protein level.  Many methods 
have been used to evaluate antigenic determinants and virulence genes of Brucella 
species and their role in infection, including transposon and signature-tagged mutagenesis 
(STM) (Ocampo-Sosa et al. 2008, Pei et al. 2007, Liautard et al. 2007, Zygmunt et al. 
2006, Wu et al. 2006, Kahl-McDonagh ad Ficht 2006, Lestrate et al. 2000 & 2003, Hong 
et al. 2000, Foulongne et al. 2000, Sangari et al. 1991, Allen et al. 1998, Smith et al. 
1987),  cellular immunoblotting (Brooks-Worrell et al. 1992a & 1992b), and deletion 
mutants (Nijskens et al. 2008, Miyoshi et al. 2007, Perry 2007, Delpino et al. 2007, 
Edmonds et al. 2002a 2002b 2001 & 2002, Phillips et al. 1997, Elzer et al. 1996 &1994).   
 Genomic mapping of several Brucella species has aided in the exploration of 
virulence factors and their effects both in vivo and in vitro.  The genome of B. melitensis 
16M was completely sequenced by Vito G. DelVecchio et al. in 2002 and several other 
strains have since been mapped from five species of Brucella.  A putative hemagglutinin 
was identified in B. melitensis (as well as B. ovis, with homologous sequences found in B. 
suis and B. canis) that was not present in the B. abortus genome.  The gene sequence for 
this putative hemagglutinin was identified as Region E and hypothesized as a significant 
virulence factor for B. melitensis.  
 Brucella hemagglutinins have been studied across several species and hosts and 
the ability of Brucella species to agglutinate red blood cells of several hosts has been 
documented (del C Rocha-Gracia 2002, Rocha et al. 1999, Zheludkov 1982, Diaz et al. 
1967).  In 1999 Rocha et al. described that Brucella strains are able to hemagglutinate 
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human, hamster and rabbit red blood cells (RBC).  From this experiment, an unnamed 
41kD surface protein was identified as a possible hemagglutinin and eukaryotic cell 
adhesion.   More recently, del C Rocha-Gracia identified a specific hemagglutinin 
(labeled SP29) in 2002 which is present on the surface of all Brucella strains tested.  
SP29 is described as a 29kD surface protein and was found to agglutinate RBC samples 
from human, rabbit, hamster, rat, and mouse sources. 
  These studies have supported the hypothesis that the region E protein has 
hemagglutinative properties, is expressed as a cell surface protein, and shows aspects of 
specificity toward a caprine host.  Furthermore, it has been shown that the addition of 
region E to RB51 increases the survivability and colonization of RB51 in the goat model, 
meriting further investigation into the potential development of an improved vaccine for 
brucellosis.  In vivo studies showed that the region E protein induces the production of 
anti-region E antibodies in the caprine host as well as an increase in the production of 
Brucella-specific antibodies following inoculation, when compared to the parental strain.  
PCR amplification data obtained using primers to the region E gene and the isolated 
DNA of RB51-QAE and 16M have suggested that it would be possible to use 
conventional PCR to detect species of Brucella that carry the region E gene sequence.  
The detection capabilities of the region E primers were similar to those observed for the 
Omp25 and Baily primers designed to detect all species of Brucella.  Although not 
confirmed, it is suggested at the region E primers, having performed similarly in control 
assays, would also be effective in detecting region E-encoding Brucella species in bodily 
fluids.  The results of conventional PCR assays using Brucella cells diluted in various 
bodily fluids supported the hypothesis that it is possible to detect the presence of Brucella 
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CFU in bodily fluids using conventional PCR.  Additional research would be needed to 
assess the full potential of using the region E, Omp25, and Baily primers to successfully 
detect Brucella cells in bodily fluids for diagnostic purposes.   These results merit further  
research into both the potential role of region E in improving the efficacy of the RB51 
vaccine, and the use of conventional PCR as a diagnostic tool for the purposes of 
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